Hypomyelinating Leukodystrophy 27

Mendelian MONDO:0958018 Pathograph 12 Show in embeddings browser Hypomyelinating leukodystrophy Ribosomopathy Autosomal recessive disease

Hypomyelinating leukodystrophy 27 is an ultra-rare autosomal recessive childhood leukodystrophy caused by biallelic hypomorphic missense variants in POLR1A, which encodes RPA194, the catalytic subunit of RNA polymerase I. Pol I transcribes ribosomal DNA into the 47S pre-rRNA, the rate-limiting first step of ribosome biogenesis, so HLD27 is a ribosomopathy that happens to present as a white-matter disease. Reported patients show ataxia, psychomotor regression, and MRI hypomyelination with cerebellar and often cerebral atrophy, progressing to severe disability; one died at 16.5 years. The disease is defined by three homozygous alleles across a handful of consanguineous families, and the whole literature is three primary clinical reports. Two points of nosology are worth stating up front, because both are easy to get wrong. First, HLD27 is not a POLR3-related leukodystrophy. dismech's existing POLR-Related_Leukodystrophy entry covers RNA polymerase III (POLR3A, POLR3B), which transcribes tRNAs and 5S rRNA. This is polymerase I, which transcribes the rDNA repeat. MONDO's "POLR-related leukodystrophy" parent groups them by name; the enzymes and their substrates are different, so the mechanism upstream of the shared hypomyelination is not shared. Only the downstream oligodendrocyte and myelin nodes are, which is why the conformance here is to the cns_myelin_failure module rather than to the POLR3 entry. Second, POLR1A is also the gene for acrofacial dysostosis, Cincinnati type, a dominant craniofacial disorder with no leukodystrophy, which dismech already carries. Same gene, opposite inheritance, non-overlapping phenotype. The founding HLD27 report notes explicitly that the mandibulofacial syndrome was absent in their family. Treat the two as an allelic series, not as a spectrum. The mechanism below is honestly uneven, and the entry marks where. Reduced rRNA transcription with aberrant rRNA processing, abnormal protein homeostasis and ER stress are demonstrated in patient fibroblasts. The nucleolar phase-separation collapse and the p53 step are inferred from Pol I model systems and general ribosomopathy biology, and neither has been shown in HLD27 CNS tissue. So is the selective vulnerability of oligodendrocytes, which is the step that actually explains why a defect in a housekeeping enzyme produces a white-matter disease.

Ask OpenScientist

Ask a research question about Hypomyelinating Leukodystrophy 27. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
7
Pathophys.
9
Phenotypes
3
Gaps
12
Pathograph
1
Genes
2
Medical Actions
3
Differentials
1
Models
6
References
1
Deep Research
👪

Inheritance

1
Autosomal recessive inheritance HP:0000007
Every confirmed patient is homozygous, and every family is consanguineous or shares ancestry. Heterozygous carriers, including the parents, are unaffected - which matters, because heterozygous POLR1A variants of a different class cause a dominant craniofacial disorder.
Autosomal recessive inheritance
Show evidence (1 reference)
PMID:28051070 SUPPORT Human Clinical
"Via linkage analysis and exome sequencing, we identified homozygous c.2801C>T (p.(Ser934Leu)) in POLR1A (encoding RPA194, largest subunit of RNA polymerase I)"
The founding homozygous variant, identified in two brothers of consanguineous parents.
?

Discussions and Knowledge Gaps

3
Why does a partial defect in a universally required housekeeping enzyme produce a disease of myelin, and what makes the oligodendrocyte lineage the cell that fails first?
KNOWLEDGE GAP OPEN gap_hld27_oligodendrocyte_selective_vulnerability
Attached to
pathophysiology#Reduced Ribosome Biogenesis and Translational Capacity pathophysiology#Deficient CNS Myelination pathophysiology#Apoptosis of Translation-Dependent Progenitors
Every cell needs ribosomes, yet HLD27 presents as a leukodystrophy. The standing explanation is translational demand: a myelinating oligodendrocyte synthesises an enormous amount of membrane and protein in a short window, so it is the first to feel a ceiling on ribosome supply. That is plausible and it is the same argument used across the ribosomopathies, but for this disease it is entirely untested. Every mechanistic experiment reported has been in fibroblasts, cancer cell lines, or zebrafish neuroepithelium and neural crest - never in oligodendrocyte lineage. The argument is also weakened by the comparison the field itself invites: the same gene, in the dominant state, produces a craniofacial disorder in which the vulnerable cell is neural crest and there is no white-matter disease at all. Something other than raw translational demand is selecting the affected tissue, and what that is has not been addressed. Patient-derived iPSC oligodendrocyte differentiation carrying the reported alleles is the obvious first experiment and has not been reported.
Does the zebrafish polr1a null tell us anything about HLD27, given that it is a null modelling a dominant craniofacial disorder and has no leukodystrophy?
HUMAN MODEL MISMATCH OPEN mismatch_hld27_no_model_of_the_defining_phenotype
Attached to
animal_models#polr1a null zebrafish pathophysiology#Apoptosis of Translation-Dependent Progenitors pathophysiology#Deficient CNS Myelination
This is a mismatch rather than a gap because good model evidence exists and is being asked to carry a claim it was not built for. The zebrafish is a homozygous null; HLD27 alleles are hypomorphic missense, and they must be, because Pol I nulls die before implantation in mouse. The model was made for acrofacial dysostosis, Cincinnati type, and its phenotype is cranioskeletal. So the p53 and translation steps in this entry are supported by an experiment in the wrong lesion, in the wrong tissue, for the wrong POLR1A disorder - and the step those steps are supposed to explain, the hypomyelination, is the one the model does not show. That failure is recorded as a FAILS_TO_RECAPITULATE link rather than left out. A knock-in of p.(Ser934Leu) or p.(Thr642Asn) in homozygosity, in an animal with myelin, is what the mechanism needs.
Proposed experiments
Homozygous hypomorphic Polr1a knock-in mouse
exp_hld27_hypomorphic_knockin_myelin_phenotype
Knock in one of the reported human missense alleles at the orthologous murine residue, breed to homozygosity, and phenotype white matter, myelin protein content and oligodendrocyte lineage progression through development - rather than using a null, which is preimplantation-lethal.
Would support
pathophysiology#Deficient CNS Myelination pathophysiology#Reduced Ribosome Biogenesis and Translational Capacity
Supporting outcome
  • Homozygous knock-in animals survive and develop reduced myelin with an arrest or loss in the oligodendrocyte lineage, reproducing the human hypomyelinating phenotype that no current model shows.
Refuting outcome
  • Homozygous knock-in animals have normal myelination despite reduced rRNA transcription, which would move the explanation for the white-matter phenotype away from translational capacity and toward something specific to human oligodendrocyte biology or to a modifier.
Patient-derived iPSC oligodendrocyte differentiation
exp_hld27_patient_ipsc_oligodendrocyte_differentiation
Differentiate iPSCs from reported patients, and isogenic corrected controls, along the oligodendrocyte lineage, measuring rRNA transcription, translational output, p53 stabilisation and myelin protein synthesis at each stage against a parallel neuronal differentiation.
Would support
pathophysiology#Reduced Ribosome Biogenesis and Translational Capacity
Would refute
pathophysiology#Apoptosis of Translation-Dependent Progenitors
Supporting outcome
  • Oligodendrocyte-lineage cells show a larger translational deficit and greater loss than neurons from the same donor, supporting differential translational demand as the reason the white matter fails first.
Refuting outcome
  • Oligodendrocyte and neuronal lineages are affected equally, or p53 is not stabilised in either, which would place the selective vulnerability outside the p53 nucleolar-stress route this entry currently draws.
Genetic tp53 inhibition partially rescues the zebrafish polr1a phenotype. Is dampening the nucleolar-stress response a plausible therapeutic direction in HLD27, or does the partial nature of that rescue rule it out?
KNOWLEDGE GAP OPEN gap_hld27_p53_inhibition_therapeutic_lead
Attached to
pathophysiology#p53 Stabilization pathophysiology#Apoptosis of Translation-Dependent Progenitors treatments#
This is the only intervention lead the POLR1A literature offers, and it is worth recording precisely because it is weaker than it first looks. In the zebrafish, removing tp53 suppresses the neuroepithelial apoptosis and partially ameliorates the phenotype - but the rescue is explicitly partial, and the authors attribute the shortfall to a failure to improve rDNA transcription and progenitor proliferation, which p53 inhibition cannot touch. So even in the model, p53 accounts for only part of the disease. Three further things would have to be true before this is a direction rather than an observation. The rescue would have to hold for a myelin phenotype, which the zebrafish does not have. It would have to hold for a hypomorphic genotype rather than a null. And transient p53 dampening during a developmental window would have to be separable from the oncogenic risk of suppressing a tumour suppressor in a child. None of the three has been addressed. The entry records the lead here rather than as a treatment, because there is no treatment.
⚙

Pathophysiology

7
Biallelic Hypomorphic POLR1A Missense Variants
Three homozygous missense alleles are known - p.(Ser934Leu), p.(Thr642Asn) and p.(Thr786Ile) - and all three sit in the catalytic core of RPA194, between the RRN3-binding region and the bridging helix. The alleles are hypomorphic rather than null, and that is not a curatorial hedge: complete Pol I loss is preimplantation-lethal in mouse, so a surviving patient necessarily retains partial activity.
oligodendrocyte CL:0000128 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves oligodendrocyte (CL:0000128). CL:0000128 is a cell type from the Cell Ontology.
POLR1A hgnc:17264 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves POLR1A (hgnc:17264). hgnc:17264 is a gene from the HUGO Gene Nomenclature Committee.
Genetic context variant_origin: GERMLINE functional_impact_category: PARTIAL_LOSS_OF_FUNCTION
Downstream
Reduced rDNA Transcription and Aberrant rRNA Processing Substitutions in the catalytic core reduce Pol I throughput.
Show evidence (4 references)
PMID:28051070 SUPPORT Human Clinical
"Our findings provide the first report showing a complex leukodystrophy associated with POLR1A."
Establishes POLR1A as the causal gene for this leukodystrophy.
PMID:36917474 SUPPORT Human Clinical
"In this report, we describe another missense variant POLR1A NM_015425.3:c.1925C>A; p.(Thr642Asn) in homozygosity in two unrelated patients."
The second allele, in two unrelated patients, which is what made the gene-disease relationship more than a single-family observation.
PMID:42271096 SUPPORT Human Clinical
"Whole-exome sequencing (WES) identified a novel homozygous variant in the proband, NM_015425.6:c.2357C > T POLR1A:p.(Thr786Ile). This variant co-segregated with the disease status within the family."
The third allele with family segregation.
+ 1 more reference
Reduced rDNA Transcription and Aberrant rRNA Processing
Less 47S pre-rRNA is made, and what is made is processed and degraded abnormally. This is the step with direct patient-derived evidence, from fibroblasts of the patient who died at 16.5 years.
RNA polymerase I complex GO:0005736 Gene Ontology (GO) Relation: this pathophysiological event involves this protein complex This pathophysiological event involves RNA polymerase I complex (GO:0005736). GO:0005736 is a protein complex from the Gene Ontology.
transcription by RNA polymerase I GO:0006360 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased transcription by RNA polymerase I (GO:0006360). GO:0006360 is a biological process from the Gene Ontology. ↓ DECREASED rRNA processing GO:0006364 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased rRNA processing (GO:0006364). GO:0006364 is a biological process from the Gene Ontology. ↓ DECREASED
nucleolus GO:0005730 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves nucleolus (GO:0005730). GO:0005730 is a cellular component from the Gene Ontology.
Downstream
Nucleolar Stress and Disturbed Nucleolar Structure
Reduced Ribosome Biogenesis and Translational Capacity
Show evidence (1 reference)
PMID:36917474 SUPPORT In Vitro
"Extensive in vitro experiments in fibroblasts from Patient 1 documented that the mutated POLR1A led to aberrant rRNA processing and degradation, and abnormal nucleolar homeostasis."
The patient-derived demonstration of the rRNA defect and of disturbed nucleolar homeostasis.
Nucleolar Stress and Disturbed Nucleolar Structure
Loss of rRNA transcription removes what holds the nucleolus together as a phase-separated compartment. Ribosomal proteins no longer consumed in assembly become free to bind MDM2, which stops MDM2 degrading p53, so p53 accumulates. This is the classic nucleolar-stress checkpoint. It is also the weakest-evidenced step in this entry. Abnormal nucleolar homeostasis is documented in patient fibroblasts; the phase-separation and p53 mechanism is transferred from Pol I knockouts, from POLR1A silencing in cancer cell lines, and from the craniofacial ribosomopathy literature. No p53 measurement has been reported in an HLD27 patient sample.
Downstream
p53 Stabilization
Show evidence (3 references)
PMID:21399665 SUPPORT INDIRECT In Vitro
"We found that a downregulation of rRNA synthesis, induced by silencing the POLR1A gene coding for the RNA polymerase I catalytic subunit, stabilised p53 without altering the nucleolar integrity in human cancer cells."
The most on-target experiment available for this step: POLR1A itself is the gene silenced. Indirect because the system is a human cancer cell line rather than a patient cell or neural tissue - and note the result complicates the story, since p53 stabilised without nucleolar disruption, so the two halves of this node are separable.
PMID:21399665 SUPPORT INDIRECT In Vitro
"p53 stabilisation was due to the inactivation of the MDM2-mediated p53 degradation by the binding of ribosomal proteins no longer used for ribosome building."
Names the MDM2 mechanism. Indirect for the same reason.
PMID:37639467 SUPPORT INDIRECT Model Organism
"We find that when Pol I function and rRNA transcription is inhibited, the viscosity of the granular compartment of the nucleolus increases, which disrupts its phase separation properties, leading to a single condensed nucleolus."
The structural half of the node. Indirect: mouse embryos and hiPSCs carrying Pol I subunit nulls, not HLD27 alleles.
p53 Stabilization
Ribosomal proteins no longer consumed in assembly bind MDM2, which stops MDM2 ubiquitinating p53, so p53 accumulates. Split from the apoptosis node below because the two sit at different scales and, more importantly, because the most on-target experiment available shows them to be separable: silencing POLR1A stabilised p53 without altering nucleolar integrity.
protein stabilization GO:0050821 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased protein stabilization (GO:0050821). GO:0050821 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Apoptosis of Translation-Dependent Progenitors
Show evidence (1 reference)
PMID:21399665 SUPPORT INDIRECT In Vitro
"p53 stabilisation was due to the inactivation of the MDM2-mediated p53 degradation by the binding of ribosomal proteins no longer used for ribosome building."
The MDM2 mechanism, in the one experiment where POLR1A itself is the gene silenced. Indirect: a human cancer cell line, not patient or neural tissue.
Apoptosis of Translation-Dependent Progenitors
Stabilised p53 drives cell-cycle arrest and apoptosis, and the cells that pay are those with the highest demand for new ribosomes. In the zebrafish polr1a null this is neuroepithelium and neural crest; the transfer to human oligodendrocyte lineage is an inference, and the entry records it as one.
oligodendrocyte precursor cell CL:0002453 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves oligodendrocyte precursor cell (CL:0002453). CL:0002453 is a cell type from the Cell Ontology.
apoptotic process GO:0006915 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased apoptotic process (GO:0006915). GO:0006915 is a biological process from the Gene Ontology. ↑ INCREASED
Animal models
polr1a null zebrafish Zebrafish recapitulates Deficient 47S rRNA transcription leads to Tp53-dependent neuroepithelial apoptosis, and genetic tp53 inhibition partially reverses the phenotype.
Downstream
Deficient CNS Myelination The step from progenitor apoptosis to hypomyelination has not been shown in HLD27 tissue; the intermediates are unknown.
Show evidence (2 references)
PMID:29750247 SUPPORT INDIRECT Model Organism
"In a zebrafish model of Acrofacial Dysostosis-Cincinnati type, we demonstrate that polr1a-/- mutants exhibit deficient 47S rRNA transcription, reduced monosomes and polysomes and, consequently, defects in protein translation. This results in Tp53-dependent neuroepithelial apoptosis, diminished..."
The clearest demonstration that polr1a loss causes Tp53-dependent apoptosis. Indirect twice over: it is a zebrafish null, and it models the dominant craniofacial disorder rather than the recessive leukodystrophy.
PMID:29750247 SUPPORT INDIRECT Model Organism
"Tp53 inhibition suppresses neuroepithelial apoptosis and partially ameliorates the polr1a mutant phenotype. However, complete rescue of cartilage development is not observed due to the failure to improve rDNA transcription and neural crest cell proliferation."
Tests the p53 step by removing it, and finds it accounts for only part of the phenotype - which is why this node is not drawn as the sole route to the clinical picture.
Reduced Ribosome Biogenesis and Translational Capacity
Fewer ribosomes means less translational capacity, and in patient fibroblasts this shows up as abnormal protein homeostasis with an ER stress response. This branch runs in parallel with the p53 branch rather than through it.
ribosome biogenesis GO:0042254 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased ribosome biogenesis (GO:0042254). GO:0042254 is a biological process from the Gene Ontology. ↓ DECREASED response to endoplasmic reticulum stress GO:0034976 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased response to endoplasmic reticulum stress (GO:0034976). GO:0034976 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Deficient CNS Myelination Myelinating oligodendrocytes have an exceptional demand for new protein, so reduced translational capacity is the plausible route to hypomyelination. The intermediate steps in oligodendrocyte biology are known in outline but have not been shown for this disease.
Show evidence (2 references)
PMID:36917474 SUPPORT In Vitro
"Proteomics data analyses and further in vitro experiments documented abnormal protein homeostasis, and endoplasmic reticulum stress responses."
The proteostasis and ER-stress findings in patient fibroblasts, which is what this node asserts.
PMID:29750247 SUPPORT INDIRECT Model Organism
"polr1a-/- mutants exhibit deficient 47S rRNA transcription, reduced monosomes and polysomes and, consequently, defects in protein translation"
Connects reduced Pol I activity to a measured translational deficit. Indirect: zebrafish null.
Deficient CNS Myelination
Myelin is laid down in insufficient amount rather than formed and then destroyed, which is what makes this a hypomyelinating rather than a demyelinating leukodystrophy. It is the shared endpoint with the other hypomyelinating leukodystrophies and the reason this entry conforms to the cns_myelin_failure module - the convergence is real even though the upstream lesion is not shared with POLR3-related disease.
oligodendrocyte CL:0000128 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves oligodendrocyte (CL:0000128). CL:0000128 is a cell type from the Cell Ontology.
central nervous system myelination GO:0022010 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased central nervous system myelination (GO:0022010). GO:0022010 is a biological process from the Gene Ontology. ↓ DECREASED
Animal models
polr1a null zebrafish Zebrafish fails to recapitulate The zebrafish polr1a null produces cranioskeletal anomalies, not a leukodystrophy. Recorded explicitly because the absence is informative: no available model reproduces the defining feature of this disease.
Downstream
CNS hypomyelination
Cerebellar atrophy
Developmental regression
Show evidence (1 reference)
PMID:36917474 SUPPORT Human Clinical
"Both patients manifested neurological deficits, with brain MRIs showing hypomyelinating leukodystrophy and cerebellar atrophy"
The imaging finding that defines the hypomyelinating pattern in both patients carrying the second allele.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Hypomyelinating Leukodystrophy 27 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

9
Musculoskeletal 2
Spasticity HP:0001257 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spasticity (HP:0001257). HP:0001257 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42271096 SUPPORT Human Clinical
"Additionally, our findings raise the possibility that POLR1A variants may be related to HSP-like phenotypes."
The spastic component of the POLR1A phenotype, reported as sufficient to suggest an HSP-like picture.
Spastic paraplegia HP:0001258 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spastic paraplegia (HP:0001258). HP:0001258 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:42271096 SUPPORT Human Clinical
"Here, we describe a fifth family harboring a novel homozygous variant in the POLR1A gene, presenting with atypical features and initially suspected of having complicated hereditary spastic paraplegia (c-HSP)."
The atypical presentation, described as the initial working diagnosis.
Nervous System 7
CNS hypomyelination HP:0003429 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is CNS hypomyelination (HP:0003429). HP:0003429 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36917474 SUPPORT Human Clinical
"Both patients manifested neurological deficits, with brain MRIs showing hypomyelinating leukodystrophy and cerebellar atrophy"
Names the pattern as hypomyelinating specifically, which is what this term asserts and the parent Leukodystrophy term does not.
Leukodystrophy HP:0002415 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Leukodystrophy (HP:0002415). HP:0002415 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:28051070 SUPPORT Human Clinical
"In two brothers born to consanguineous parents, we identified an unusual neurological disease that manifested with ataxia, psychomotor retardation, cerebellar and cerebral atrophy, and leukodystrophy."
The founding clinical description, naming leukodystrophy alongside the atrophy and the motor and cognitive features.
PMID:42271096 REFUTE Human Clinical
"Our findings further expand the genetic and clinical spectrum of POLR1A-related disorders by identifying a novel variant and a distinct clinical manifestation characterized by a c-HSP-like phenotype, without apparent hypomyelination."
Curated as REFUTE against the claim that hypomyelination is obligate in this disorder, not against the disorder-phenotype association itself. The same authors note hypomyelination may still develop later, so this is a limit on the defining feature rather than a second disease.
Cerebellar atrophy HP:0001272 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebellar atrophy (HP:0001272), qualified as course progressive. HP:0001272 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:36917474 SUPPORT Human Clinical
"Both patients manifested neurological deficits, with brain MRIs showing hypomyelinating leukodystrophy and cerebellar atrophy"
Documents cerebellar atrophy on MRI in both patients.
Cerebral atrophy HP:0002059 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebral atrophy (HP:0002059). HP:0002059 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28051070 SUPPORT Human Clinical
"an unusual neurological disease that manifested with ataxia, psychomotor retardation, cerebellar and cerebral atrophy, and leukodystrophy"
Names cerebral as well as cerebellar atrophy in the founding family.
Ataxia HP:0001251 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ataxia (HP:0001251). HP:0001251 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28051070 SUPPORT Human Clinical
"an unusual neurological disease that manifested with ataxia, psychomotor retardation, cerebellar and cerebral atrophy, and leukodystrophy"
Names ataxia as part of the presenting syndrome.
Developmental regression HP:0002376 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Developmental regression (HP:0002376), qualified as course progressive. HP:0002376 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (2 references)
PMID:36917474 SUPPORT Human Clinical
"Patient 1 had progressive disease course, leading to death at the age of 16.5 years."
Documents the progressive course and its outcome in the one patient followed to death.
PMID:36917474 SUPPORT Human Clinical
"We confirm that POLR1A biallelic variants cause neurodegenerative disease, expand the knowledge of the clinical phenotype of the disorder"
The authors' classification of the disorder as neurodegenerative, which is what "regression" rather than "delay" encodes.
Abnormal basal ganglia morphology HP:0002134 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal basal ganglia morphology (HP:0002134). HP:0002134 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36917474 SUPPORT Human Clinical
"and in Patient 1 additionally with hypointensity of globi pallidi and small volume of the basal ganglia."
The single-patient imaging finding, quoted with the "in Patient 1 additionally" framing that makes its restriction to one case explicit.
🧬

Genetic Associations

1
POLR1A (Causal biallelic variant)
Gene: POLR1A hgnc:17264 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is POLR1A (hgnc:17264). hgnc:17264 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (3 references)
PMID:28051070 SUPPORT Human Clinical
"Although in silico analysis, histopathologic evidence and functional verification indicated that both variants were deleterious, segregation with the patient phenotype established that the POLR1A defect underlies the disease, as a clinically unaffected sister also was homozygous for the OSBPL11 variant."
Worth quoting in full because it is how the gene was assigned: the family carried a second homozygous candidate in OSBPL11, and it was an unaffected homozygous sister who excluded it. The gene-disease relationship rests on that segregation, not on the variant's predicted deleteriousness.
PMID:28051070 SUPPORT Human Clinical
"Of those, POLR1C is also implicated in a mandibulofacial dysostosis syndrome without leukodystrophy as POLR1A is. This syndrome is absent in the family we present."
The authors' own statement that the craniofacial allelic disorder was not present in their leukodystrophy family - the basis for treating the two as separate entities rather than a spectrum.
PMID:42271096 SUPPORT Human Clinical
"The systematic review identified a total of 27 variants in the POLR1A gene, three of which were linked to HLD27."
Puts the HLD27 allelic spectrum in proportion against POLR1A variation as a whole - 3 of 27 reported variants.
💊

Medical Actions

2
Supportive and rehabilitative care
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Platform: Behavioral / lifestyle
There is no disease-modifying therapy. Management is rehabilitation for the motor and cognitive deficits, spasticity management, and the usual supportive care of a progressive childhood leukodystrophy, with genetic counselling for the family.
Show evidence (1 reference)
PMID:36917474 SUPPORT INDIRECT Human Clinical
"Patient 1 had progressive disease course, leading to death at the age of 16.5 years."
Recorded as the basis for a purely supportive posture: the only reported long-term outcome is a progressive course to death, with no intervention reported to alter it. Indirect because this is a natural-history observation rather than an evaluation of supportive care.
Genetic counselling
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Platform: Behavioral / lifestyle
A 25 per cent recurrence risk for siblings once the biallelic variant is known. Counselling also has to cover the allelic dominant disorder, because a heterozygous POLR1A finding in a relative means something quite different from carrier status for this disease.
Show evidence (1 reference)
PMID:28051070 SUPPORT INDIRECT Human Clinical
"In two brothers born to consanguineous parents, we identified an unusual neurological disease"
Establishes the recessive, consanguineous setting that the recurrence-risk counselling addresses. Indirect: the paper reports the family structure, not a counselling intervention.
🔬

Diagnosis

3
Whole-exome sequencing
All five families were solved by exome sequencing, in two cases after the clinical picture had pointed somewhere else entirely. Given that one proband was worked up as complicated hereditary spastic paraplegia, a targeted leukodystrophy panel would not reliably find this gene.
Results: A homozygous POLR1A missense variant in the catalytic core of RPA194, segregating with disease.
Show evidence (1 reference)
PMID:42271096 SUPPORT Human Clinical
"These findings underscore the critical importance of WES in the diagnosis of complicated disorders, particularly in patients with atypical or difficult-to-interpret clinical presentations."
The authors' own conclusion about the diagnostic route, drawn from a case that presented atypically.
Brain MRI
The imaging signature is diffuse hypomyelination with cerebellar and often cerebral atrophy. A normal-appearing white matter does not exclude the diagnosis: the fifth proband had no apparent hypomyelination at presentation.
Results: Hypomyelinating leukodystrophy with cerebellar atrophy; in one patient also globus pallidus hypointensity with small basal ganglia.
Show evidence (1 reference)
PMID:36917474 SUPPORT Human Clinical
"Both patients manifested neurological deficits, with brain MRIs showing hypomyelinating leukodystrophy and cerebellar atrophy"
The MRI findings this recommendation is based on.
Patient fibroblast studies of rRNA and nucleolar function
Not a routine diagnostic test, but the assay that established the mechanism and that would be needed to call a novel POLR1A missense variant functionally hypomorphic. Reduced nucleolar RPA194 by immunostaining distinguished affected brothers from an unaffected homozygous sibling in the founding family.
Results: Decreased nucleolar RPA194; aberrant rRNA processing and degradation; abnormal nucleolar homeostasis; abnormal protein homeostasis with ER stress.
Show evidence (1 reference)
PMID:28051070 SUPPORT In Vitro
"Decreased nucleolar RPA194 was observed in the skin fibroblasts of only the affected brothers"
The functional readout, and the "only the affected brothers" contrast that makes it informative rather than merely descriptive.
📊

Prevalence

1
Worldwide
Cases In Literature Ultra Rare
No population estimate exists and none is likely to. The count is the literature: four families before the 2026 systematic review, five after it. Recorded as CASES_IN_LITERATURE rather than a rate, because a rate would imply an ascertainment denominator that does not exist.
Show evidence (1 reference)
PMID:42271096 SUPPORT Human Clinical
"Homozygous variants in POLR1A cause an ultra-rare disorder known as hypomyelinating leukodystrophy type-27 (HLD27) with only four families reported worldwide to date."
The published family count immediately before this report added the fifth.
🔀

Differential Diagnoses

3

Conditions with similar clinical presentations that must be differentiated from Hypomyelinating Leukodystrophy 27:

Acrofacial dysostosis, Cincinnati type MONDO:0014651
Overlapping Features Not a clinical differential - nobody would confuse a craniofacial dysostosis with a leukodystrophy - but a genetic one, and the more dangerous for it. It is the same gene, and it dominates the POLR1A entries in variant databases. A heterozygous POLR1A missense finding is far more likely to be about this disorder than about HLD27.
Distinguishing Features
  • Heterozygous dominant rather than biallelic recessive
  • Mandibulofacial dysostosis with limb anomalies
  • No leukodystrophy
Show evidence (1 reference)
PMID:28051070 SUPPORT Human Clinical
"Of those, POLR1C is also implicated in a mandibulofacial dysostosis syndrome without leukodystrophy as POLR1A is. This syndrome is absent in the family we present."
States that the allelic craniofacial syndrome was absent in the leukodystrophy family.
Complicated hereditary spastic paraplegia MONDO:0019064
Overlapping Features Included because a reported patient was investigated as c-HSP before exome sequencing found POLR1A. This is a differential in the practical direction that matters: not "could this leukodystrophy be HSP" but "could this HSP be POLR1A".
Distinguishing Features
  • Hypomyelination on MRI, which may be absent early in POLR1A disease
  • Cerebellar atrophy
  • Biallelic POLR1A variants on exome sequencing
Show evidence (1 reference)
PMID:42271096 SUPPORT Human Clinical
"Additionally, our findings raise the possibility that POLR1A variants may be related to HSP-like phenotypes."
The authors' proposal that POLR1A belongs on the HSP differential, which is the direction this entry records.
🐁

Animal Models

1
polr1a null zebrafish
The only in vivo model with mechanistic depth for this gene, and it was made for the other POLR1A disorder. It supplies the p53 step and the translational deficit; it cannot supply the leukodystrophy, which it does not have.
Species
Zebrafish
Genotype
polr1a homozygous null
Publication
PMID:29750247
Pathograph links
Apoptosis of Translation-Dependent Progenitors recapitulates fidelity: moderate observes: cellular Deficient 47S rRNA transcription leads to Tp53-dependent neuroepithelial apoptosis, and genetic tp53 inhibition partially reverses the phenotype.
Limitations: A homozygous null modelling a dominant craniofacial disorder, used here to support a step in a recessive hypomorphic leukodystrophy. The cells that die are neuroepithelium and neural crest, not oligodendrocyte lineage, and the animal has no white-matter phenotype. The rescue is also only partial, so p53 is not the whole mechanism even in the model.
Readouts
Neuroepithelial apoptosis
Direction: INCREASED
Interpretation: Apoptosis of translation-dependent progenitors as the cellular readout of nucleolar stress.
Show evidence (1 reference)
PMID:29750247 SUPPORT Model Organism
"This results in Tp53-dependent neuroepithelial apoptosis, diminished neural crest cell proliferation and cranioskeletal anomalies."
The apoptosis measurement behind this readout.
Apoptosis after genetic tp53 inhibition
Direction: RESTORED
Interpretation: The rescue arm. Removing tp53 suppresses the apoptosis, which is what makes the p53 step causal in this model rather than correlated.
Show evidence (1 reference)
PMID:29750247 SUPPORT Model Organism
"Tp53 inhibition suppresses neuroepithelial apoptosis and partially ameliorates the polr1a mutant phenotype."
The rescue result, including the word "partially", which is the part that limits the claim.
Show evidence (1 reference)
PMID:29750247 SUPPORT Model Organism
"This indicates that POLR1A is critical for rRNA transcription, which is considered a rate limiting step in ribosome biogenesis, underpinning its requirement for neuroepithelial cell and neural crest cell proliferation and survival."
The authors' summary of what the model establishes about POLR1A, which is why it is treated as informative for this node.
Deficient CNS Myelination fails to recapitulate fidelity: low observes: tissue The zebrafish polr1a null produces cranioskeletal anomalies, not a leukodystrophy. Recorded explicitly because the absence is informative: no available model reproduces the defining feature of this disease.
Limitations: The published phenotype is craniofacial and neuroepithelial. No myelin or white-matter phenotype is reported, and a homozygous null is in any case the wrong lesion for a hypomorphic recessive disorder - Pol I nulls are preimplantation-lethal in mouse, so the surviving human patients cannot be modelled by one.
Show evidence (2 references)
PMID:29750247 SUPPORT Model Organism
"This results in Tp53-dependent neuroepithelial apoptosis, diminished neural crest cell proliferation and cranioskeletal anomalies."
The reported phenotype is cranioskeletal. Cited here as the record of what the model does produce, against which the absence of a myelin phenotype is the negative claim.
+ 1 more reference
{ }

Source YAML

click to show 
name: Hypomyelinating Leukodystrophy 27
creation_date: "2026-09-11T11:40:00Z"
category: Mendelian
synonyms:
- HLD27
- POLR1A-related leukodystrophy
- POLR1A-related hypomyelinating leukodystrophy
description: >-
  Hypomyelinating leukodystrophy 27 is an ultra-rare autosomal recessive
  childhood leukodystrophy caused by biallelic hypomorphic missense variants in
  POLR1A, which encodes RPA194, the catalytic subunit of RNA polymerase I. Pol I
  transcribes ribosomal DNA into the 47S pre-rRNA, the rate-limiting first step
  of ribosome biogenesis, so HLD27 is a ribosomopathy that happens to present as
  a white-matter disease.

  Reported patients show ataxia, psychomotor regression, and MRI hypomyelination
  with cerebellar and often cerebral atrophy, progressing to severe disability;
  one died at 16.5 years. The disease is defined by three homozygous alleles
  across a handful of consanguineous families, and the whole literature is
  three primary clinical reports.

  Two points of nosology are worth stating up front, because both are easy to
  get wrong.

  First, HLD27 is not a POLR3-related leukodystrophy. dismech's existing
  POLR-Related_Leukodystrophy entry covers RNA polymerase III (POLR3A, POLR3B),
  which transcribes tRNAs and 5S rRNA. This is polymerase I, which transcribes
  the rDNA repeat. MONDO's "POLR-related leukodystrophy" parent groups them by
  name; the enzymes and their substrates are different, so the mechanism
  upstream of the shared hypomyelination is not shared. Only the downstream
  oligodendrocyte and myelin nodes are, which is why the conformance here is to
  the cns_myelin_failure module rather than to the POLR3 entry.

  Second, POLR1A is also the gene for acrofacial dysostosis, Cincinnati type, a
  dominant craniofacial disorder with no leukodystrophy, which dismech already
  carries. Same gene, opposite inheritance, non-overlapping phenotype. The
  founding HLD27 report notes explicitly that the mandibulofacial syndrome was
  absent in their family. Treat the two as an allelic series, not as a spectrum.

  The mechanism below is honestly uneven, and the entry marks where. Reduced
  rRNA transcription with aberrant rRNA processing, abnormal protein homeostasis
  and ER stress are demonstrated in patient fibroblasts. The nucleolar
  phase-separation collapse and the p53 step are inferred from Pol I model
  systems and general ribosomopathy biology, and neither has been shown in HLD27
  CNS tissue. So is the selective vulnerability of oligodendrocytes, which is
  the step that actually explains why a defect in a housekeeping enzyme produces
  a white-matter disease.
disease_term:
  preferred_term: leukodystrophy, hypomyelinating, 27
  term:
    id: MONDO:0958018
    label: leukodystrophy, hypomyelinating, 27
parents:
- Hypomyelinating leukodystrophy
- Ribosomopathy
- Autosomal recessive disease
references:
- reference: PMID:28051070
  title: Severe neurodegenerative disease in brothers with homozygous mutation in POLR1A.
- reference: PMID:36917474
  title: A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis.
- reference: PMID:42271096
  title: "A novel homozygous variant in the POLR1A gene: a complicated hereditary spastic paraplegia (c-HSP) or a hypomyelinating leukodystrophy type-27 (HLD27) phenotype?"
- reference: PMID:29750247
  title: tp53-dependent and independent signaling underlies the pathogenesis and possible prevention of Acrofacial Dysostosis-Cincinnati type.
- reference: PMID:21399665
  title: The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells.
- reference: PMID:37639467
  title: rRNA transcription is integral to phase separation and maintenance of nucleolar structure.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    Every confirmed patient is homozygous, and every family is consanguineous or
    shares ancestry. Heterozygous carriers, including the parents, are
    unaffected - which matters, because heterozygous POLR1A variants of a
    different class cause a dominant craniofacial disorder.
  evidence:
  - reference: PMID:28051070
    reference_title: Severe neurodegenerative disease in brothers with homozygous mutation in POLR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Via linkage analysis and exome sequencing, we identified homozygous c.2801C>T (p.(Ser934Leu)) in POLR1A (encoding RPA194, largest subunit of RNA polymerase I)
    explanation: >-
      The founding homozygous variant, identified in two brothers of
      consanguineous parents.
prevalence:
- population: Worldwide
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    No population estimate exists and none is likely to. The count is the
    literature: four families before the 2026 systematic review, five after it.
    Recorded as CASES_IN_LITERATURE rather than a rate, because a rate would
    imply an ascertainment denominator that does not exist.
  evidence:
  - reference: PMID:42271096
    reference_title: "A novel homozygous variant in the POLR1A gene: a complicated hereditary spastic paraplegia (c-HSP) or a hypomyelinating leukodystrophy type-27 (HLD27) phenotype?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Homozygous variants in POLR1A cause an ultra-rare disorder known as hypomyelinating leukodystrophy type-27 (HLD27) with only four families reported worldwide to date.
    explanation: >-
      The published family count immediately before this report added the fifth.
pathophysiology:
- name: Biallelic Hypomorphic POLR1A Missense Variants
  biological_scale: MOLECULAR
  conforms_to: "cns_myelin_failure#Oligodendrocyte-Lineage or Myelin-Membrane Insult"
  description: >-
    Three homozygous missense alleles are known - p.(Ser934Leu), p.(Thr642Asn)
    and p.(Thr786Ile) - and all three sit in the catalytic core of RPA194,
    between the RRN3-binding region and the bridging helix. The alleles are
    hypomorphic rather than null, and that is not a curatorial hedge: complete
    Pol I loss is preimplantation-lethal in mouse, so a surviving patient
    necessarily retains partial activity.
  genetic_context:
    variant_origin: GERMLINE
    functional_impact_category: PARTIAL_LOSS_OF_FUNCTION
  genes:
  - preferred_term: POLR1A
    term:
      id: hgnc:17264
      label: POLR1A
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  downstream:
  - target: Reduced rDNA Transcription and Aberrant rRNA Processing
    causal_link_type: DIRECT
    description: >-
      Substitutions in the catalytic core reduce Pol I throughput.
  evidence:
  - reference: PMID:28051070
    reference_title: Severe neurodegenerative disease in brothers with homozygous mutation in POLR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our findings provide the first report showing a complex leukodystrophy associated with POLR1A.
    explanation: >-
      Establishes POLR1A as the causal gene for this leukodystrophy.
  - reference: PMID:36917474
    reference_title: A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In this
      report, we describe another missense variant POLR1A NM_015425.3:c.1925C>A;
      p.(Thr642Asn) in homozygosity in two unrelated patients.
    explanation: >-
      The second allele, in two unrelated patients, which is what made the
      gene-disease relationship more than a single-family observation.
  - reference: PMID:42271096
    reference_title: "A novel homozygous variant in the POLR1A gene: a complicated hereditary spastic paraplegia (c-HSP) or a hypomyelinating leukodystrophy type-27 (HLD27) phenotype?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Whole-exome sequencing (WES) identified a novel homozygous variant in the proband, NM_015425.6:c.2357C > T POLR1A:p.(Thr786Ile). This variant co-segregated with the disease status within the family.
    explanation: >-
      The third allele with family segregation.
  - reference: PMID:37639467
    reference_title: rRNA transcription is integral to phase separation and maintenance of nucleolar structure.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Here we show that homozygous null mutations in Pol I subunits required for rRNA transcription and ribosome biogenesis lead to preimplantation lethality.
    explanation: >-
      Supports reading the human alleles as hypomorphic rather than null.
      Indirect: the inference is that a viable patient cannot carry complete
      loss of function, which follows from the mouse result rather than being
      measured in patients.
- name: Reduced rDNA Transcription and Aberrant rRNA Processing
  biological_scale: MOLECULAR
  description: >-
    Less 47S pre-rRNA is made, and what is made is processed and degraded
    abnormally. This is the step with direct patient-derived evidence, from
    fibroblasts of the patient who died at 16.5 years.
  biological_processes:
  - preferred_term: transcription by RNA polymerase I
    modifier: DECREASED
    term:
      id: GO:0006360
      label: transcription by RNA polymerase I
  - preferred_term: rRNA processing
    modifier: DECREASED
    term:
      id: GO:0006364
      label: rRNA processing
  cellular_components:
  - preferred_term: nucleolus
    term:
      id: GO:0005730
      label: nucleolus
  protein_complexes:
  - preferred_term: RNA polymerase I complex
    term:
      id: GO:0005736
      label: RNA polymerase I complex
  downstream:
  - target: Nucleolar Stress and Disturbed Nucleolar Structure
    causal_link_type: DIRECT
  - target: Reduced Ribosome Biogenesis and Translational Capacity
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:36917474
    reference_title: A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Extensive in vitro
      experiments in fibroblasts from Patient 1 documented that the mutated POLR1A led
      to aberrant rRNA processing and degradation, and abnormal nucleolar homeostasis.
    explanation: >-
      The patient-derived demonstration of the rRNA defect and of disturbed
      nucleolar homeostasis.
- name: Nucleolar Stress and Disturbed Nucleolar Structure
  biological_scale: CELLULAR
  description: >-
    Loss of rRNA transcription removes what holds the nucleolus together as a
    phase-separated compartment. Ribosomal proteins no longer consumed in
    assembly become free to bind MDM2, which stops MDM2 degrading p53, so p53
    accumulates. This is the classic nucleolar-stress checkpoint.

    It is also the weakest-evidenced step in this entry. Abnormal nucleolar
    homeostasis is documented in patient fibroblasts; the phase-separation and
    p53 mechanism is transferred from Pol I knockouts, from POLR1A silencing in
    cancer cell lines, and from the craniofacial ribosomopathy literature. No
    p53 measurement has been reported in an HLD27 patient sample.
  downstream:
  - target: p53 Stabilization
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:21399665
    reference_title: The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    snippet: >-
      We found that a downregulation of rRNA synthesis, induced by silencing the POLR1A gene coding for the RNA polymerase I catalytic subunit, stabilised p53 without altering the nucleolar integrity in human cancer cells.
    explanation: >-
      The most on-target experiment available for this step: POLR1A itself is
      the gene silenced. Indirect because the system is a human cancer cell
      line rather than a patient cell or neural tissue - and note the result
      complicates the story, since p53 stabilised without nucleolar disruption,
      so the two halves of this node are separable.
  - reference: PMID:21399665
    reference_title: The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    snippet: >-
      p53 stabilisation was due to the inactivation of the MDM2-mediated p53 degradation by the binding of ribosomal proteins no longer used for ribosome building.
    explanation: >-
      Names the MDM2 mechanism. Indirect for the same reason.
  - reference: PMID:37639467
    reference_title: rRNA transcription is integral to phase separation and maintenance of nucleolar structure.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      We find that when Pol I function and rRNA transcription is inhibited, the viscosity of the granular compartment of the nucleolus increases, which disrupts its phase separation properties, leading to a single condensed nucleolus.
    explanation: >-
      The structural half of the node. Indirect: mouse embryos and hiPSCs
      carrying Pol I subunit nulls, not HLD27 alleles.
- name: p53 Stabilization
  biological_scale: MOLECULAR
  description: >-
    Ribosomal proteins no longer consumed in assembly bind MDM2, which stops
    MDM2 ubiquitinating p53, so p53 accumulates. Split from the apoptosis node
    below because the two sit at different scales and, more importantly, because
    the most on-target experiment available shows them to be separable: silencing
    POLR1A stabilised p53 without altering nucleolar integrity.
  biological_processes:
  - preferred_term: protein stabilization
    modifier: INCREASED
    term:
      id: GO:0050821
      label: protein stabilization
  downstream:
  - target: Apoptosis of Translation-Dependent Progenitors
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:21399665
    reference_title: The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    snippet: >-
      p53 stabilisation was due to the inactivation of the MDM2-mediated p53 degradation by the binding of ribosomal proteins no longer used for ribosome building.
    explanation: >-
      The MDM2 mechanism, in the one experiment where POLR1A itself is the gene
      silenced. Indirect: a human cancer cell line, not patient or neural tissue.
- name: Apoptosis of Translation-Dependent Progenitors
  biological_scale: CELLULAR
  description: >-
    Stabilised p53 drives cell-cycle arrest and apoptosis, and the cells that
    pay are those with the highest demand for new ribosomes. In the zebrafish
    polr1a null this is neuroepithelium and neural crest; the transfer to human
    oligodendrocyte lineage is an inference, and the entry records it as one.
  biological_processes:
  - preferred_term: apoptotic process
    modifier: INCREASED
    term:
      id: GO:0006915
      label: apoptotic process
  cell_types:
  - preferred_term: oligodendrocyte precursor cell
    term:
      id: CL:0002453
      label: oligodendrocyte precursor cell
  downstream:
  - target: Deficient CNS Myelination
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      The step from progenitor apoptosis to hypomyelination has not been shown
      in HLD27 tissue; the intermediates are unknown.
  evidence:
  - reference: PMID:29750247
    reference_title: tp53-dependent and independent signaling underlies the pathogenesis and possible prevention of Acrofacial Dysostosis-Cincinnati type.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In a zebrafish model of Acrofacial Dysostosis-Cincinnati type, we demonstrate that polr1a-/- mutants exhibit deficient 47S rRNA transcription, reduced monosomes and polysomes and, consequently, defects in protein translation. This results in Tp53-dependent neuroepithelial apoptosis, diminished neural crest cell proliferation and cranioskeletal anomalies.
    explanation: >-
      The clearest demonstration that polr1a loss causes Tp53-dependent
      apoptosis. Indirect twice over: it is a zebrafish null, and it models the
      dominant craniofacial disorder rather than the recessive leukodystrophy.
  - reference: PMID:29750247
    reference_title: tp53-dependent and independent signaling underlies the pathogenesis and possible prevention of Acrofacial Dysostosis-Cincinnati type.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Tp53 inhibition suppresses neuroepithelial apoptosis and partially ameliorates the polr1a mutant phenotype. However, complete rescue of cartilage development is not observed due to the failure to improve rDNA transcription and neural crest cell proliferation.
    explanation: >-
      Tests the p53 step by removing it, and finds it accounts for only part of
      the phenotype - which is why this node is not drawn as the sole route to
      the clinical picture.
- name: Reduced Ribosome Biogenesis and Translational Capacity
  biological_scale: CELLULAR
  description: >-
    Fewer ribosomes means less translational capacity, and in patient
    fibroblasts this shows up as abnormal protein homeostasis with an ER stress
    response. This branch runs in parallel with the p53 branch rather than
    through it.
  biological_processes:
  - preferred_term: ribosome biogenesis
    modifier: DECREASED
    term:
      id: GO:0042254
      label: ribosome biogenesis
  - preferred_term: response to endoplasmic reticulum stress
    modifier: INCREASED
    term:
      id: GO:0034976
      label: response to endoplasmic reticulum stress
  downstream:
  - target: Deficient CNS Myelination
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Myelinating oligodendrocytes have an exceptional demand for new protein,
      so reduced translational capacity is the plausible route to
      hypomyelination. The intermediate steps in oligodendrocyte biology are
      known in outline but have not been shown for this disease.
  evidence:
  - reference: PMID:36917474
    reference_title: A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Proteomics data analyses and further in vitro experiments documented abnormal
      protein homeostasis, and endoplasmic reticulum stress responses.
    explanation: >-
      The proteostasis and ER-stress findings in patient fibroblasts, which is
      what this node asserts.
  - reference: PMID:29750247
    reference_title: tp53-dependent and independent signaling underlies the pathogenesis and possible prevention of Acrofacial Dysostosis-Cincinnati type.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      polr1a-/- mutants exhibit deficient 47S rRNA transcription, reduced monosomes and polysomes and, consequently, defects in protein translation
    explanation: >-
      Connects reduced Pol I activity to a measured translational deficit.
      Indirect: zebrafish null.
- name: Deficient CNS Myelination
  biological_scale: TISSUE
  conforms_to: "cns_myelin_failure#Deficient or Unstable CNS Myelin Sheath"
  description: >-
    Myelin is laid down in insufficient amount rather than formed and then
    destroyed, which is what makes this a hypomyelinating rather than a
    demyelinating leukodystrophy. It is the shared endpoint with the other
    hypomyelinating leukodystrophies and the reason this entry conforms to the
    cns_myelin_failure module - the convergence is real even though the upstream
    lesion is not shared with POLR3-related disease.
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  biological_processes:
  - preferred_term: central nervous system myelination
    modifier: DECREASED
    term:
      id: GO:0022010
      label: central nervous system myelination
  downstream:
  - target: CNS hypomyelination
    causal_link_type: DIRECT
  - target: Cerebellar atrophy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Developmental regression
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:36917474
    reference_title: A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Both patients manifested
      neurological deficits, with brain MRIs showing hypomyelinating leukodystrophy
      and cerebellar atrophy
    explanation: >-
      The imaging finding that defines the hypomyelinating pattern in both
      patients carrying the second allele.
phenotypes:
- name: CNS hypomyelination
  category: Neurologic
  diagnostic: true
  description: >-
    Myelin deposited in insufficient amount rather than laid down and then lost.
    This is the specific claim the entry's whole argument rests on, and it is
    bound separately from the general leukodystrophy term because the
    hypomyelinating-versus-demyelinating distinction is what places this
    disorder with the POLR3-related and PLP1 diseases rather than with
    metachromatic leukodystrophy or Krabbe disease.
  phenotype_term:
    preferred_term: CNS hypomyelination
    term:
      id: HP:0003429
      label: CNS hypomyelination
  evidence:
  - reference: PMID:36917474
    reference_title: A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Both patients manifested
      neurological deficits, with brain MRIs showing hypomyelinating leukodystrophy
      and cerebellar atrophy
    explanation: >-
      Names the pattern as hypomyelinating specifically, which is what this term
      asserts and the parent Leukodystrophy term does not.
- name: Spasticity
  category: Neurologic
  description: >-
    Variable, and distinct from the spastic paraplegia of the atypical fifth
    family - spasticity is a sign that appears across the reported cases, while
    the c-HSP presentation is a whole clinical picture that led to a different
    working diagnosis.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:42271096
    reference_title: "A novel homozygous variant in the POLR1A gene: a complicated hereditary spastic paraplegia (c-HSP) or a hypomyelinating leukodystrophy type-27 (HLD27) phenotype?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additionally, our findings raise the possibility that POLR1A variants may be related to HSP-like phenotypes.
    explanation: >-
      The spastic component of the POLR1A phenotype, reported as sufficient to
      suggest an HSP-like picture.
- name: Leukodystrophy
  category: Neurologic
  diagnostic: true
  description: >-
    Diffuse hypomyelination of cerebral white matter on MRI. It is the defining
    finding and the reason the disorder is named as it is - but it is not
    obligate: the fifth family's proband was worked up as complicated hereditary
    spastic paraplegia without apparent hypomyelination.
  phenotype_term:
    preferred_term: Leukodystrophy
    term:
      id: HP:0002415
      label: Leukodystrophy
  evidence:
  - reference: PMID:28051070
    reference_title: Severe neurodegenerative disease in brothers with homozygous mutation in POLR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In two brothers born to consanguineous parents, we identified an unusual neurological disease that manifested with ataxia, psychomotor retardation, cerebellar and cerebral atrophy, and leukodystrophy.
    explanation: >-
      The founding clinical description, naming leukodystrophy alongside the
      atrophy and the motor and cognitive features.
  - reference: PMID:42271096
    reference_title: "A novel homozygous variant in the POLR1A gene: a complicated hereditary spastic paraplegia (c-HSP) or a hypomyelinating leukodystrophy type-27 (HLD27) phenotype?"
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Our findings further expand the genetic and clinical spectrum of POLR1A-related disorders by identifying a novel variant and a distinct clinical manifestation characterized by a c-HSP-like phenotype, without apparent hypomyelination.
    explanation: >-
      Curated as REFUTE against the claim that hypomyelination is obligate in
      this disorder, not against the disorder-phenotype association itself. The
      same authors note hypomyelination may still develop later, so this is a
      limit on the defining feature rather than a second disease.
- name: Cerebellar atrophy
  category: Neurologic
  diagnostic: true
  description: >-
    Present in the founding family and in both patients carrying the second
    allele. Together with hypomyelination it forms the imaging signature.
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:36917474
    reference_title: A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Both patients manifested
      neurological deficits, with brain MRIs showing hypomyelinating leukodystrophy
      and cerebellar atrophy
    explanation: >-
      Documents cerebellar atrophy on MRI in both patients.
- name: Cerebral atrophy
  category: Neurologic
  description: >-
    Reported in the founding family alongside the cerebellar atrophy, so the
    degeneration is not confined to the cerebellum.
  phenotype_term:
    preferred_term: Cerebral atrophy
    term:
      id: HP:0002059
      label: Cerebral atrophy
  evidence:
  - reference: PMID:28051070
    reference_title: Severe neurodegenerative disease in brothers with homozygous mutation in POLR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      an unusual neurological disease that manifested with ataxia, psychomotor retardation, cerebellar and cerebral atrophy, and leukodystrophy
    explanation: >-
      Names cerebral as well as cerebellar atrophy in the founding family.
- name: Ataxia
  category: Neurologic
  description: >-
    A presenting feature in the founding family, consistent with the cerebellar
    involvement.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:28051070
    reference_title: Severe neurodegenerative disease in brothers with homozygous mutation in POLR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      an unusual neurological disease that manifested with ataxia, psychomotor retardation, cerebellar and cerebral atrophy, and leukodystrophy
    explanation: >-
      Names ataxia as part of the presenting syndrome.
- name: Developmental regression
  category: Neurologic
  diagnostic: true
  description: >-
    Loss of acquired milestones rather than a static delay. The distinction
    matters clinically: this is a neurodegenerative course, and in one patient
    it ended in death at 16.5 years.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:36917474
    reference_title: A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patient 1 had progressive
      disease course, leading to death at the age of 16.5 years.
    explanation: >-
      Documents the progressive course and its outcome in the one patient
      followed to death.
  - reference: PMID:36917474
    reference_title: A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      We confirm that
      POLR1A biallelic variants cause neurodegenerative disease, expand the knowledge
      of the clinical phenotype of the disorder
    explanation: >-
      The authors' classification of the disorder as neurodegenerative, which is
      what "regression" rather than "delay" encodes.
- name: Abnormal basal ganglia morphology
  category: Neurologic
  description: >-
    Globus pallidus T2 hypointensity with small basal ganglia volume, reported
    in one patient only. Recorded because it is a specific imaging finding that
    might narrow a differential, not because it is established as a feature of
    the disorder - a single patient is a single patient.
  phenotype_term:
    preferred_term: Abnormal basal ganglia morphology
    term:
      id: HP:0002134
      label: Abnormal basal ganglia morphology
  evidence:
  - reference: PMID:36917474
    reference_title: A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      and in Patient 1 additionally with hypointensity of
      globi pallidi and small volume of the basal ganglia.
    explanation: >-
      The single-patient imaging finding, quoted with the "in Patient 1
      additionally" framing that makes its restriction to one case explicit.
- name: Spastic paraplegia
  category: Neurologic
  description: >-
    The fifth family's proband presented as complicated hereditary spastic
    paraplegia and was investigated as such. This widens the differential
    considerably: POLR1A would not normally be on an HSP gene panel.
  phenotype_term:
    preferred_term: Spastic paraplegia
    term:
      id: HP:0001258
      label: Spastic paraplegia
  evidence:
  - reference: PMID:42271096
    reference_title: "A novel homozygous variant in the POLR1A gene: a complicated hereditary spastic paraplegia (c-HSP) or a hypomyelinating leukodystrophy type-27 (HLD27) phenotype?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Here, we describe a fifth family harboring a novel homozygous variant in the POLR1A gene, presenting with atypical features and initially suspected of having complicated hereditary spastic paraplegia (c-HSP).
    explanation: >-
      The atypical presentation, described as the initial working diagnosis.
genetic:
- name: POLR1A
  association: Causal biallelic variant
  gene_term:
    preferred_term: POLR1A
    term:
      id: hgnc:17264
      label: POLR1A
  frequency: The only gene associated with HLD27.
  notes: >-
    Three homozygous missense alleles are reported: p.(Ser934Leu),
    p.(Thr642Asn) and p.(Thr786Ile). All lie in the catalytic core of RPA194.

    The allelic relationship with acrofacial dysostosis, Cincinnati type is the
    thing to understand about this gene. That disorder is dominant,
    craniofacial, and carries no leukodystrophy; this one is recessive,
    neurological, and carries no mandibulofacial dysostosis. The founding HLD27
    report states outright that the mandibulofacial syndrome was absent in their
    family. A POLR1A variant therefore cannot be interpreted without its
    zygosity and its position, and a laboratory reporting "POLR1A pathogenic"
    against a ClinVar record dominated by the dominant phenotype is not
    answering the question a leukodystrophy referral asks.
  evidence:
  - reference: PMID:28051070
    reference_title: Severe neurodegenerative disease in brothers with homozygous mutation in POLR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Although in silico analysis, histopathologic evidence and functional verification indicated that both variants were deleterious, segregation with the patient phenotype established that the POLR1A defect underlies the disease, as a clinically unaffected sister also was homozygous for the OSBPL11 variant.
    explanation: >-
      Worth quoting in full because it is how the gene was assigned: the family
      carried a second homozygous candidate in OSBPL11, and it was an unaffected
      homozygous sister who excluded it. The gene-disease relationship rests on
      that segregation, not on the variant's predicted deleteriousness.
  - reference: PMID:28051070
    reference_title: Severe neurodegenerative disease in brothers with homozygous mutation in POLR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of those, POLR1C is also implicated in a mandibulofacial dysostosis syndrome without leukodystrophy as POLR1A is. This syndrome is absent in the family we present.
    explanation: >-
      The authors' own statement that the craniofacial allelic disorder was not
      present in their leukodystrophy family - the basis for treating the two as
      separate entities rather than a spectrum.
  - reference: PMID:42271096
    reference_title: "A novel homozygous variant in the POLR1A gene: a complicated hereditary spastic paraplegia (c-HSP) or a hypomyelinating leukodystrophy type-27 (HLD27) phenotype?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The systematic review identified a total of 27 variants in the POLR1A gene, three of which were linked to HLD27.
    explanation: >-
      Puts the HLD27 allelic spectrum in proportion against POLR1A variation as
      a whole - 3 of 27 reported variants.
treatments:
- name: Supportive and rehabilitative care
  description: >-
    There is no disease-modifying therapy. Management is rehabilitation for the
    motor and cognitive deficits, spasticity management, and the usual
    supportive care of a progressive childhood leukodystrophy, with genetic
    counselling for the family.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:36917474
    reference_title: A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Patient 1 had progressive
      disease course, leading to death at the age of 16.5 years.
    explanation: >-
      Recorded as the basis for a purely supportive posture: the only reported
      long-term outcome is a progressive course to death, with no intervention
      reported to alter it. Indirect because this is a natural-history
      observation rather than an evaluation of supportive care.
- name: Genetic counselling
  description: >-
    A 25 per cent recurrence risk for siblings once the biallelic variant is
    known. Counselling also has to cover the allelic dominant disorder, because
    a heterozygous POLR1A finding in a relative means something quite different
    from carrier status for this disease.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:28051070
    reference_title: Severe neurodegenerative disease in brothers with homozygous mutation in POLR1A.
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In two brothers born to consanguineous parents, we identified an unusual neurological disease
    explanation: >-
      Establishes the recessive, consanguineous setting that the recurrence-risk
      counselling addresses. Indirect: the paper reports the family structure,
      not a counselling intervention.
diagnosis:
- name: Whole-exome sequencing
  description: >-
    All five families were solved by exome sequencing, in two cases after the
    clinical picture had pointed somewhere else entirely. Given that one proband
    was worked up as complicated hereditary spastic paraplegia, a targeted
    leukodystrophy panel would not reliably find this gene.
  results: >-
    A homozygous POLR1A missense variant in the catalytic core of RPA194,
    segregating with disease.
  evidence:
  - reference: PMID:42271096
    reference_title: "A novel homozygous variant in the POLR1A gene: a complicated hereditary spastic paraplegia (c-HSP) or a hypomyelinating leukodystrophy type-27 (HLD27) phenotype?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      These findings underscore the critical importance of WES in the diagnosis of complicated disorders, particularly in patients with atypical or difficult-to-interpret clinical presentations.
    explanation: >-
      The authors' own conclusion about the diagnostic route, drawn from a case
      that presented atypically.
- name: Brain MRI
  description: >-
    The imaging signature is diffuse hypomyelination with cerebellar and often
    cerebral atrophy. A normal-appearing white matter does not exclude the
    diagnosis: the fifth proband had no apparent hypomyelination at
    presentation.
  results: >-
    Hypomyelinating leukodystrophy with cerebellar atrophy; in one patient also
    globus pallidus hypointensity with small basal ganglia.
  evidence:
  - reference: PMID:36917474
    reference_title: A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Both patients manifested
      neurological deficits, with brain MRIs showing hypomyelinating leukodystrophy
      and cerebellar atrophy
    explanation: >-
      The MRI findings this recommendation is based on.
- name: Patient fibroblast studies of rRNA and nucleolar function
  description: >-
    Not a routine diagnostic test, but the assay that established the mechanism
    and that would be needed to call a novel POLR1A missense variant
    functionally hypomorphic. Reduced nucleolar RPA194 by immunostaining
    distinguished affected brothers from an unaffected homozygous sibling in the
    founding family.
  results: >-
    Decreased nucleolar RPA194; aberrant rRNA processing and degradation;
    abnormal nucleolar homeostasis; abnormal protein homeostasis with ER stress.
  evidence:
  - reference: PMID:28051070
    reference_title: Severe neurodegenerative disease in brothers with homozygous mutation in POLR1A.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: >-
      Decreased nucleolar RPA194 was observed in the skin fibroblasts of only the affected brothers
    explanation: >-
      The functional readout, and the "only the affected brothers" contrast that
      makes it informative rather than merely descriptive.
differential_diagnoses:
- name: POLR-related leukodystrophy (POLR3-associated)
  description: >-
    The disorder HLD27 is most likely to be filed under by mistake, because
    MONDO groups both beneath a "POLR-related leukodystrophy" parent and the
    names are nearly identical. The enzymes are not. POLR3A and POLR3B are
    subunits of RNA polymerase III, which transcribes tRNAs and 5S rRNA; POLR1A
    is polymerase I, which transcribes the rDNA repeat into 47S pre-rRNA. The
    founding HLD27 report places the two side by side and notes the POLR3
    disorders begin later. Note that dismech's entry under this MONDO term is
    the POLR3 one (POLR3A, POLR3B); the term itself is a parent that
    nominally spans both polymerases, which is the source of the confusion
    this differential exists to head off.
  disease_term:
    preferred_term: POLR-related leukodystrophy
    term:
      id: MONDO:0100605
      label: POLR-related leukodystrophy
  distinguishing_features:
  - RNA polymerase III rather than polymerase I
  - Later onset than the POLR1A disease
  - Hypodontia and hypogonadotropic hypogonadism in the classic 4H phenotype
  evidence:
  - reference: PMID:28051070
    reference_title: Severe neurodegenerative disease in brothers with homozygous mutation in POLR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Variants in three other RNA polymerase subunits, POLR1C, POLR3A and POLR3B, are known to cause recessive leukodystrophy similar to the disease afflicting the present family but with a later onset.
    explanation: >-
      Names the polymerase III disorders as the clinical neighbours and gives
      the onset difference that separates them.
- name: Acrofacial dysostosis, Cincinnati type
  description: >-
    Not a clinical differential - nobody would confuse a craniofacial dysostosis
    with a leukodystrophy - but a genetic one, and the more dangerous for it. It
    is the same gene, and it dominates the POLR1A entries in variant databases.
    A heterozygous POLR1A missense finding is far more likely to be about this
    disorder than about HLD27.
  disease_term:
    preferred_term: acrofacial dysostosis Cincinnati type
    term:
      id: MONDO:0014651
      label: acrofacial dysostosis Cincinnati type
  distinguishing_features:
  - Heterozygous dominant rather than biallelic recessive
  - Mandibulofacial dysostosis with limb anomalies
  - No leukodystrophy
  evidence:
  - reference: PMID:28051070
    reference_title: Severe neurodegenerative disease in brothers with homozygous mutation in POLR1A.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Of those, POLR1C is also implicated in a mandibulofacial dysostosis syndrome without leukodystrophy as POLR1A is. This syndrome is absent in the family we present.
    explanation: >-
      States that the allelic craniofacial syndrome was absent in the
      leukodystrophy family.
- name: Complicated hereditary spastic paraplegia
  description: >-
    Included because a reported patient was investigated as c-HSP before exome
    sequencing found POLR1A. This is a differential in the practical direction
    that matters: not "could this leukodystrophy be HSP" but "could this HSP be
    POLR1A".
  disease_term:
    preferred_term: hereditary spastic paraplegia
    term:
      id: MONDO:0019064
      label: hereditary spastic paraplegia
  distinguishing_features:
  - Hypomyelination on MRI, which may be absent early in POLR1A disease
  - Cerebellar atrophy
  - Biallelic POLR1A variants on exome sequencing
  evidence:
  - reference: PMID:42271096
    reference_title: "A novel homozygous variant in the POLR1A gene: a complicated hereditary spastic paraplegia (c-HSP) or a hypomyelinating leukodystrophy type-27 (HLD27) phenotype?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Additionally, our findings raise the possibility that POLR1A variants may be related to HSP-like phenotypes.
    explanation: >-
      The authors' proposal that POLR1A belongs on the HSP differential, which
      is the direction this entry records.
animal_models:
- name: polr1a null zebrafish
  species: Zebrafish
  genotype: polr1a homozygous null
  publication: PMID:29750247
  description: >-
    The only in vivo model with mechanistic depth for this gene, and it was made
    for the other POLR1A disorder. It supplies the p53 step and the translational
    deficit; it cannot supply the leukodystrophy, which it does not have.
  modeled_mechanisms:
  - target: Apoptosis of Translation-Dependent Progenitors
    relationship: RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      Deficient 47S rRNA transcription leads to Tp53-dependent neuroepithelial
      apoptosis, and genetic tp53 inhibition partially reverses the phenotype.
    limitations: >-
      A homozygous null modelling a dominant craniofacial disorder, used here to
      support a step in a recessive hypomorphic leukodystrophy. The cells that
      die are neuroepithelium and neural crest, not oligodendrocyte lineage, and
      the animal has no white-matter phenotype. The rescue is also only partial,
      so p53 is not the whole mechanism even in the model.
    readouts:
    - name: Neuroepithelial apoptosis
      target: Apoptosis of Translation-Dependent Progenitors
      direction: INCREASED
      interpretation: >-
        Apoptosis of translation-dependent progenitors as the cellular readout
        of nucleolar stress.
      evidence:
      - reference: PMID:29750247
        reference_title: tp53-dependent and independent signaling underlies the pathogenesis and possible prevention of Acrofacial Dysostosis-Cincinnati type.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          This results in Tp53-dependent neuroepithelial apoptosis, diminished neural crest cell proliferation and cranioskeletal anomalies.
        explanation: >-
          The apoptosis measurement behind this readout.
    - name: Apoptosis after genetic tp53 inhibition
      target: Apoptosis of Translation-Dependent Progenitors
      direction: RESTORED
      interpretation: >-
        The rescue arm. Removing tp53 suppresses the apoptosis, which is what
        makes the p53 step causal in this model rather than correlated.
      evidence:
      - reference: PMID:29750247
        reference_title: tp53-dependent and independent signaling underlies the pathogenesis and possible prevention of Acrofacial Dysostosis-Cincinnati type.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Tp53 inhibition suppresses neuroepithelial apoptosis and partially ameliorates the polr1a mutant phenotype.
        explanation: >-
          The rescue result, including the word "partially", which is the part
          that limits the claim.
    evidence:
    - reference: PMID:29750247
      reference_title: tp53-dependent and independent signaling underlies the pathogenesis and possible prevention of Acrofacial Dysostosis-Cincinnati type.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        This indicates that POLR1A is critical for rRNA transcription, which is considered a rate limiting step in ribosome biogenesis, underpinning its requirement for neuroepithelial cell and neural crest cell proliferation and survival.
      explanation: >-
        The authors' summary of what the model establishes about POLR1A, which
        is why it is treated as informative for this node.
  - target: Deficient CNS Myelination
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    model_scale: TISSUE
    description: >-
      The zebrafish polr1a null produces cranioskeletal anomalies, not a
      leukodystrophy. Recorded explicitly because the absence is informative: no
      available model reproduces the defining feature of this disease.
    limitations: >-
      The published phenotype is craniofacial and neuroepithelial. No myelin or
      white-matter phenotype is reported, and a homozygous null is in any case
      the wrong lesion for a hypomorphic recessive disorder - Pol I nulls are
      preimplantation-lethal in mouse, so the surviving human patients cannot be
      modelled by one.
    evidence:
    - reference: PMID:29750247
      reference_title: tp53-dependent and independent signaling underlies the pathogenesis and possible prevention of Acrofacial Dysostosis-Cincinnati type.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        This results in Tp53-dependent neuroepithelial apoptosis, diminished neural crest cell proliferation and cranioskeletal anomalies.
      explanation: >-
        The reported phenotype is cranioskeletal. Cited here as the record of
        what the model does produce, against which the absence of a myelin
        phenotype is the negative claim.
    - reference: PMID:37639467
      reference_title: rRNA transcription is integral to phase separation and maintenance of nucleolar structure.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: >-
        Here we show that homozygous null mutations in Pol I subunits required for rRNA transcription and ribosome biogenesis lead to preimplantation lethality.
      explanation: >-
        Explains why no mammalian null model of this disease exists, and so why
        the modelling gap is structural rather than an oversight.
discussions:
- discussion_id: gap_hld27_oligodendrocyte_selective_vulnerability
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Why does a partial defect in a universally required housekeeping enzyme
    produce a disease of myelin, and what makes the oligodendrocyte lineage the
    cell that fails first?
  attaches_to:
  - pathophysiology#Reduced Ribosome Biogenesis and Translational Capacity
  - pathophysiology#Deficient CNS Myelination
  - pathophysiology#Apoptosis of Translation-Dependent Progenitors
  rationale: >-
    Every cell needs ribosomes, yet HLD27 presents as a leukodystrophy. The
    standing explanation is translational demand: a myelinating oligodendrocyte
    synthesises an enormous amount of membrane and protein in a short window, so
    it is the first to feel a ceiling on ribosome supply. That is plausible and
    it is the same argument used across the ribosomopathies, but for this
    disease it is entirely untested. Every mechanistic experiment reported has
    been in fibroblasts, cancer cell lines, or zebrafish neuroepithelium and
    neural crest - never in oligodendrocyte lineage. The argument is also
    weakened by the comparison the field itself invites: the same gene, in the
    dominant state, produces a craniofacial disorder in which the vulnerable
    cell is neural crest and there is no white-matter disease at all. Something
    other than raw translational demand is selecting the affected tissue, and
    what that is has not been addressed. Patient-derived iPSC oligodendrocyte
    differentiation carrying the reported alleles is the obvious first
    experiment and has not been reported.
- discussion_id: mismatch_hld27_no_model_of_the_defining_phenotype
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Does the zebrafish polr1a null tell us anything about HLD27, given that it
    is a null modelling a dominant craniofacial disorder and has no
    leukodystrophy?
  attaches_to:
  - animal_models#polr1a null zebrafish
  - pathophysiology#Apoptosis of Translation-Dependent Progenitors
  - pathophysiology#Deficient CNS Myelination
  rationale: >-
    This is a mismatch rather than a gap because good model evidence exists and
    is being asked to carry a claim it was not built for. The zebrafish is a
    homozygous null; HLD27 alleles are hypomorphic missense, and they must be,
    because Pol I nulls die before implantation in mouse. The model was made for
    acrofacial dysostosis, Cincinnati type, and its phenotype is cranioskeletal.
    So the p53 and translation steps in this entry are supported by an
    experiment in the wrong lesion, in the wrong tissue, for the wrong
    POLR1A disorder - and the step those steps are supposed to explain, the
    hypomyelination, is the one the model does not show. That failure is recorded
    as a FAILS_TO_RECAPITULATE link rather than left out. A knock-in of
    p.(Ser934Leu) or p.(Thr642Asn) in homozygosity, in an animal with myelin,
    is what the mechanism needs.
  proposed_experiments:
  - experiment_id: exp_hld27_hypomorphic_knockin_myelin_phenotype
    name: Homozygous hypomorphic Polr1a knock-in mouse
    description: >-
      Knock in one of the reported human missense alleles at the orthologous
      murine residue, breed to homozygosity, and phenotype white matter, myelin
      protein content and oligodendrocyte lineage progression through
      development - rather than using a null, which is preimplantation-lethal.
    would_support:
    - pathophysiology#Deficient CNS Myelination
    - pathophysiology#Reduced Ribosome Biogenesis and Translational Capacity
    supporting_outcome:
    - >-
      Homozygous knock-in animals survive and develop reduced myelin with an
      arrest or loss in the oligodendrocyte lineage, reproducing the human
      hypomyelinating phenotype that no current model shows.
    refuting_outcome:
    - >-
      Homozygous knock-in animals have normal myelination despite reduced rRNA
      transcription, which would move the explanation for the white-matter
      phenotype away from translational capacity and toward something specific
      to human oligodendrocyte biology or to a modifier.
  - experiment_id: exp_hld27_patient_ipsc_oligodendrocyte_differentiation
    name: Patient-derived iPSC oligodendrocyte differentiation
    description: >-
      Differentiate iPSCs from reported patients, and isogenic corrected
      controls, along the oligodendrocyte lineage, measuring rRNA transcription,
      translational output, p53 stabilisation and myelin protein synthesis at
      each stage against a parallel neuronal differentiation.
    would_support:
    - pathophysiology#Reduced Ribosome Biogenesis and Translational Capacity
    would_refute:
    - pathophysiology#Apoptosis of Translation-Dependent Progenitors
    supporting_outcome:
    - >-
      Oligodendrocyte-lineage cells show a larger translational deficit and
      greater loss than neurons from the same donor, supporting differential
      translational demand as the reason the white matter fails first.
    refuting_outcome:
    - >-
      Oligodendrocyte and neuronal lineages are affected equally, or p53 is not
      stabilised in either, which would place the selective vulnerability
      outside the p53 nucleolar-stress route this entry currently draws.
- discussion_id: gap_hld27_p53_inhibition_therapeutic_lead
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Genetic tp53 inhibition partially rescues the zebrafish polr1a phenotype.
    Is dampening the nucleolar-stress response a plausible therapeutic direction
    in HLD27, or does the partial nature of that rescue rule it out?
  attaches_to:
  - pathophysiology#p53 Stabilization
  - pathophysiology#Apoptosis of Translation-Dependent Progenitors
  - treatments#
  rationale: >-
    This is the only intervention lead the POLR1A literature offers, and it is
    worth recording precisely because it is weaker than it first looks. In the
    zebrafish, removing tp53 suppresses the neuroepithelial apoptosis and
    partially ameliorates the phenotype - but the rescue is explicitly partial,
    and the authors attribute the shortfall to a failure to improve rDNA
    transcription and progenitor proliferation, which p53 inhibition cannot
    touch. So even in the model, p53 accounts for only part of the disease.

    Three further things would have to be true before this is a direction rather
    than an observation. The rescue would have to hold for a myelin phenotype,
    which the zebrafish does not have. It would have to hold for a hypomorphic
    genotype rather than a null. And transient p53 dampening during a
    developmental window would have to be separable from the oncogenic risk of
    suppressing a tumour suppressor in a child. None of the three has been
    addressed. The entry records the lead here rather than as a treatment,
    because there is no treatment.
notes: >-
  Three things about this entry.

  The evidence is deliberately uneven and marked as such. The upstream steps -
  reduced rRNA transcription, aberrant rRNA processing, abnormal protein
  homeostasis and ER stress - are demonstrated in patient fibroblasts and carry
  IN_VITRO evidence with no directness qualifier. The nucleolar phase-separation
  and p53 steps carry directness: INDIRECT throughout, because every experiment
  supporting them was done in a Pol I null, a cancer cell line, or zebrafish
  neural crest. The gap between those two tiers is the substance of the
  knowledge-gap discussion, and flattening it would misrepresent what is known
  about this disease.

  The conformance target is cns_myelin_failure, not the POLR3 entry. Sharing an
  endpoint is not sharing a mechanism, and RNA polymerase I and RNA polymerase
  III transcribe different things. Only the oligodendrocyte and myelin-sheath
  nodes are genuinely common, and those are exactly the two nodes the module
  supplies.

  On the term bindings: several HPO CURIEs suggested by the deep-research report
  named the wrong concept. HP:0002500 was offered as "Leukodystrophy" but is
  Abnormal cerebral white matter morphology; HP:0002451 was offered as "Basal
  ganglia abnormality" but is Limb dystonia. Every term in this entry was read
  out of cache/hp/terms.csv or resolved with runoak rather than taken from a
  suggestion. That applies to review suggestions too: HP:0007266, proposed in
  review as "CNS hypomyelination", resolves to Cerebral dysmyelination, which
  is a different concept - dysmyelination is abnormal myelin composition,
  hypomyelination is insufficient deposition, and the distinction is the
  entry's central claim. The term bound here is HP:0003429.
📚

References & Deep Research

References

6
PMID:28051070
Severe neurodegenerative disease in brothers with homozygous mutation in POLR1A.
No top-level findings curated for this source.
PMID:36917474
A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis.
No top-level findings curated for this source.
PMID:42271096
A novel homozygous variant in the POLR1A gene: a complicated hereditary spastic paraplegia (c-HSP) or a hypomyelinating leukodystrophy type-27 (HLD27) phenotype?
No top-level findings curated for this source.
PMID:29750247
tp53-dependent and independent signaling underlies the pathogenesis and possible prevention of Acrofacial Dysostosis-Cincinnati type.
No top-level findings curated for this source.
PMID:21399665
The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells.
No top-level findings curated for this source.
PMID:37639467
rRNA transcription is integral to phase separation and maintenance of nucleolar structure.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (3)

Record notes

Three things about this entry. The evidence is deliberately uneven and marked as such. The upstream steps - reduced rRNA transcription, aberrant rRNA processing, abnormal protein homeostasis and ER stress - are demonstrated in patient fibroblasts and carry IN_VITRO evidence with no directness qualifier. The nucleolar phase-separation and p53 steps carry directness: INDIRECT throughout, because every experiment supporting them was done in a Pol I null, a cancer cell line, or zebrafish neural crest. The gap between those two tiers is the substance of the knowledge-gap discussion, and flattening it would misrepresent what is known about this disease. The conformance target is cns_myelin_failure, not the POLR3 entry. Sharing an endpoint is not sharing a mechanism, and RNA polymerase I and RNA polymerase III transcribe different things. Only the oligodendrocyte and myelin-sheath nodes are genuinely common, and those are exactly the two nodes the module supplies. On the term bindings: several HPO CURIEs suggested by the deep-research report named the wrong concept. HP:0002500 was offered as "Leukodystrophy" but is Abnormal cerebral white matter morphology; HP:0002451 was offered as "Basal ganglia abnormality" but is Limb dystonia. Every term in this entry was read out of cache/hp/terms.csv or resolved with runoak rather than taken from a suggestion. That applies to review suggestions too: HP:0007266, proposed in review as "CNS hypomyelination", resolves to Cerebral dysmyelination, which is a different concept - dysmyelination is abnormal myelin composition, hypomyelination is insufficient deposition, and the distinction is the entry's central claim. The term bound here is HP:0003429.

Review round 1: ontology bindings on conformer nodes, hypomyelination term, node split · 2026-09-11T13:15:18Z · View source

Addresses the ai4c-reviewer REQUEST_CHANGES review on PR #11681. Both blocking items taken, plus most of the suggestions. Single bundled push. BLOCKING. - Both conforms_to nodes now carry ontology bindings: CL:0000128 oligodendrocyte on the trigger node and on Deficient CNS Myelination, plus GO:0042552 myelination DECREASED on the myelination node. This was a real omission - the entry's headline knowledge gap is about oligodendrocyte selective vulnerability and the cell type appeared nowhere machine-readable. - Added a CNS hypomyelination phenotype, but bound to HP:0003429, NOT the HP:0007266 proposed in review. HP:0007266 resolves to 'Cerebral dysmyelination' (verified with runoak against ols:hp). Dysmyelination and hypomyelination are different concepts - abnormal myelin composition versus insufficient deposition - and the hypomyelinating-versus-demyelinating distinction is the entry's central claim, so the suggested term would have asserted the opposite of what the entry argues. Also added HP:0001257 Spasticity as suggested. SUGGESTIONS TAKEN. - Split the bundled 'p53 Stabilization and Apoptosis of Translation-Dependent Progenitors' node into 'p53 Stabilization' (MOLECULAR) and 'Apoptosis of Translation-Dependent Progenitors' (CELLULAR), with CL:0002453 oligodendrocyte precursor cell on the latter. All downstream targets, attaches_to refs and animal-model link targets repointed; check_entity_ref_foreign_keys and check-causal-targets both clean afterwards. - Added GO:0006364 rRNA processing and the GO:0005736 RNA polymerase I complex protein-complex binding to the Pol I node. - Added a discussion recording the p53-inhibition preclinical lead, framed around why it is weaker than it looks: the zebrafish rescue is explicitly partial, the model has no myelin phenotype, it is a null rather than a hypomorph, and p53 suppression in a child carries oncogenic risk. NOT TAKEN. - Named physical-therapy and occupational-therapy treatments: none of the references cited by this entry states that either intervention is used in this disease, so a named treatment could carry no exact-quote evidence. The generic Supportive Care block stays, and its description already names rehabilitation and spasticity management without asserting a specific intervention. Note NCIT:C15271, proposed in review as physical therapy, resolves to Liver Transplantation; the correct term would be NCIT:C15302, but the binding is not the blocker here, the absence of a citable source is. - gnomAD constraint metrics and ClinVar counts: the report obtained these by direct database query rather than from a citable publication, so there is no reference to attach an exact-quote snippet to. Adding them would mean an unevidenced numeric claim. - Pruning the seven 'uncited' references_cache files: they are cited by the committed deep-research report, which CI checks for citation coverage, so they are owned by this PR rather than screening residue. Validation: just validate-disorders clean with 43/43 snippets verified (up from 40/40); schema, terms, duplicate-keys, entity-refs, causal-targets, enum-values all OK; conforms_to anchors resolve after the node split.

Create: Hypomyelinating Leukodystrophy 27 · 2026-09-11T12:26:27Z · View source

De novo curation of hypomyelinating leukodystrophy 27 (MONDO:0958018, POLR1A) from one openscientist deep-research report plus direct reading of every cited reference in references_cache/. preflight-dr returned WARN, not PASS: the rival-gene heuristic flagged MDM2 at 27% of POLR1A mentions. Inspected every MDM2 mention before proceeding - all are the p53/MDM2 nucleolar-stress checkpoint, i.e. the disease mechanism, not a second disease entity. OMIM xref (620675) and causal gene both match the intended MONDO term, so the report was used. Two nosological calls recorded in the entry: (1) HLD27 is polymerase I, not polymerase III, so conformance is to the cns_myelin_failure module rather than to dismech's POLR-Related_Leukodystrophy entry (POLR3A/POLR3B); the convergence is at the oligodendrocyte and myelin-sheath nodes only. (2) POLR1A is allelic with acrofacial dysostosis Cincinnati type - dominant, craniofacial, no leukodystrophy - which dismech already carries; the founding report states the mandibulofacial syndrome was absent in their family. Evidence tiering is the substance of this entry. Reduced rRNA transcription, aberrant rRNA processing, abnormal protein homeostasis and ER stress carry IN_VITRO evidence from patient fibroblasts with no directness qualifier. The nucleolar phase-separation and p53 steps carry directness: INDIRECT throughout, because every supporting experiment is a Pol I null, a cancer cell line, or zebrafish neural crest. A HUMAN_MODEL_MISMATCH discussion records that the only in vivo model is a homozygous polr1a null built for the dominant craniofacial disorder, and the FAILS_TO_RECAPITULATE link against Deficient CNS Myelination states that no available model reproduces the defining phenotype. The atypical fifth family is curated as supports: REFUTE against the claim that hypomyelination is obligate, not against the disease-phenotype association. Errors caught during curation: the report offered HP:0002500 as 'Leukodystrophy' (it is Abnormal cerebral white matter morphology; the correct term is HP:0002415) and HP:0002451 as 'Basal ganglia abnormality' (it is Limb dystonia; the correct term is HP:0002134). Two MONDO CURIEs written from memory - MONDO:0024239 and MONDO:0060615 - resolved to congenital anomaly of cardiovascular system and to nothing at all; replaced with MONDO:0100605 and MONDO:0014651 read out of existing KB entries. One reference_title was completed from memory after a truncated terminal read and did not match the cached title; corrected programmatically from references_cache frontmatter. Validation: just validate-disorders clean with 40/40 snippets verified; schema, terms, duplicate-keys, entity-refs, causal-targets, qualifier-terms, enum-values, reference-titles all OK; check_conforms_to_module_node_references returns no issues.

OpenScientist ▸
Hypomyelinating Leukodystrophy 27 (HLD27): A Comprehensive Disease Report
openscientist-autonomous 16 citations 2026-09-11T12:05:17.716876

Hypomyelinating Leukodystrophy 27 (HLD27): A Comprehensive Disease Report

Disease: Hypomyelinating Leukodystrophy 27 (HLD27) MONDO ID: MONDO:0958018 · OMIM: #620675 · Gene: POLR1A (HGNC:17264) Category: Genetic — autosomal recessive ribosomopathy / hypomyelinating leukodystrophy

Summary

Hypomyelinating Leukodystrophy 27 (HLD27; OMIM #620675, MONDO:0958018) is an ultra-rare, autosomal-recessive, childhood-onset hypomyelinating leukodystrophy caused by biallelic hypomorphic missense variants in POLR1A, the gene encoding RPA194 (also called RPA1/A190), the catalytic (largest) subunit of RNA polymerase I (Pol I). Pol I is the enzyme that transcribes ribosomal DNA into the 47S pre-ribosomal RNA precursor, the rate-limiting first step of ribosome biogenesis. As of 2026 the disease has been reported in only ~5 families / ≈9 patients worldwide, defined by three homozygous alleles: p.(Ser934Leu), p.(Thr642Asn), and p.(Thr786Ile). This makes HLD27 one of the rarest genetically defined leukodystrophies.

Mechanistically, HLD27 is a ribosomopathy. Partial loss of Pol I catalytic activity reduces 47S rRNA transcription and produces aberrant rRNA processing/degradation and disturbed nucleolar homeostasis. This triggers a nucleolar stress response in which free ribosomal proteins bind and inhibit MDM2, stabilizing p53; downstream consequences include impaired translational capacity and endoplasmic reticulum (ER)-stress/protein-homeostasis defects. Cell types with the highest translational demand — including neural progenitors and myelinating oligodendrocytes — are selectively vulnerable, producing the observed hypomyelination with progressive cerebellar and cerebral atrophy, ataxia, psychomotor regression, and variable spasticity. The same gene, when carrying heterozygous dominant variants, causes an entirely distinct disorder — acrofacial dysostosis, Cincinnati type — illustrating striking allele- and dose-dependent pleiotropy.

There is no disease-modifying therapy; management is supportive and rehabilitative, combined with genetic counseling for at-risk families. A significant preclinical therapeutic lead comes from zebrafish and mouse polr1a models, in which p53 (tp53) pathway inhibition partially rescues the ribosomopathy phenotype, nominating the nucleolar-stress/p53 axis as a candidate intervention point. The human evidence base is small but internally consistent and appears saturated at three primary clinical reports.

1. Disease Information

Overview. HLD27 is a genetically determined hypomyelinating leukodystrophy — a disorder of the central nervous system (CNS) white matter in which myelin is deposited in deficient amounts (hypomyelination) rather than being formed normally and subsequently destroyed (demyelination). It presents in infancy or childhood with progressive neurological deterioration and characteristic MRI findings of diffuse, persistent T2/FLAIR hyperintensity of the white matter together with cerebellar (and often cerebral) atrophy.

Key identifiers:

Resource Identifier
Disease name Hypomyelinating Leukodystrophy 27 (HLD27)
OMIM (phenotype) #620675
MONDO MONDO:0958018
Causal gene POLR1A
OMIM (gene) 616404
HGNC HGNC:17264
NCBI Gene (Entrez) 25885
Ensembl ENSG00000068654
UniProt O95602
Cytoband 2p11.2

Synonyms / aliases (gene product): RPA194, RPA1, RPA190, A190, AFDCIN, HLD27, DNA-directed RNA polymerase I subunit RPA1.

Nature of the information. The disease-level knowledge is derived almost entirely from aggregated case reports and small case series (individual patients described in the primary literature), together with mechanistic data from cell lines and model organisms, rather than from large EHR-derived cohorts or registries. Given the extreme rarity, no population registry data exist.

2. Etiology

Primary cause — genetic. HLD27 is caused exclusively by biallelic (homozygous or compound-heterozygous) pathogenic variants in POLR1A. All confirmed cases to date are homozygous, arising in the context of consanguinity or shared ancestry. There is no known environmental, infectious, or acquired cause; environmental and lifestyle factors are not applicable as disease initiators.

The founding report identified "homozygous c.2801C>T (p.(Ser934Leu)) in POLR1A (encoding RPA194, largest subunit of RNA polymerase I)" in two brothers of consanguineous parents (PMID: 28051070).

Genetic risk factors. The causal variants are the risk factor; being a biallelic carrier confers disease. Consanguinity is the principal epidemiological risk context because it raises the probability of homozygosity for a rare recessive allele. No independent susceptibility loci or GWAS signals exist for this Mendelian disorder.

Modifier genes. None have been formally identified for HLD27. Genotype–phenotype correlation suggests the specific POLR1A allele itself is the primary determinant of phenotype severity and character (see Section 4). Because the mechanism converges on p53/nucleolar stress, genes in the p53–MDM2–ribosomal-protein axis are plausible but unproven modifiers.

Protective factors. None documented. No protective variants or dietary/lifestyle protective exposures are known.

Gene–environment interactions. None established. HLD27 is a monogenic disorder with essentially full penetrance in biallelic individuals; environmental modulation has not been reported.

3. Phenotypes

The core phenotype is a progressive neurodegenerative encephalopathy with hypomyelinating leukodystrophy. Because so few patients are described, frequencies are qualitative.

Phenotype Type HPO term (suggested) Onset Frequency (qualitative)
Hypomyelinating leukodystrophy (MRI) Neuroimaging / lab HP:0002500 (Leukodystrophy); HP:0007266 (CNS hypomyelination) Infancy–childhood Core feature (most patients)
Cerebellar atrophy Clinical sign / imaging HP:0001272 Childhood Highly frequent
Cerebral atrophy Clinical sign / imaging HP:0002059 Childhood Frequent
Ataxia Symptom / sign HP:0001251 Childhood Frequent
Psychomotor regression / retardation Sign HP:0002376 (Developmental regression); HP:0001263 Infancy–childhood Core feature
Spasticity Sign HP:0001257 Variable Variable
Globus pallidus T2 hypointensity / small basal ganglia Imaging HP:0002451 (Basal ganglia abnormality) Childhood Reported (Misceo patient 1)

Age of onset. Neonatal to early-childhood in the classic hypomyelinating presentations; the atypical spastic-paraplegia-like case presented as complicated hereditary spastic paraplegia (c-HSP). Onset is generally pediatric.

Severity and progression. Severe and progressive. In the founding family the course was described as "an unusual neurological disease that manifested with ataxia, psychomotor retardation, cerebellar and cerebral atrophy, and leukodystrophy" (PMID: 28051070). In the Misceo cohort, patient 1 followed a progressive course and died at 16.5 years (PMID: 36917474).

Phenotypic variability. A fifth family carrying p.(Thr786Ile) presented atypically, "initially suspected of having complicated hereditary spastic paraplegia (c-HSP), without apparent hypomyelination" (PMID: 42271096), demonstrating that the phenotype spans classic hypomyelinating leukodystrophy through to an HSP-like presentation in which hypomyelination may be absent or emerge later.

Quality-of-life impact. Not formally measured with instruments (EQ-5D/SF-36) in this ultra-rare population. Based on the clinical descriptions, impact is profound: progressive loss of motor and cognitive milestones, ataxia, and spasticity produce severe disability and dependence, with premature death reported.

4. Genetic / Molecular Information

Causal gene — POLR1A (HGNC:17264; Entrez 25885; OMIM gene 616404; UniProt O95602; Ensembl ENSG00000068654; chromosome 2p11.2). It encodes RPA194 (RPA1), the 1,720-amino-acid catalytic core subunit of the 13-subunit RNA polymerase I complex.

Reported HLD27 pathogenic variants (all homozygous, recessive):

Variant (cDNA) Protein Family / report Phenotype notes PMID
c.2801C>T p.(Ser934Leu) Family 1 — two brothers, consanguineous Ataxia, psychomotor retardation, cerebellar + cerebral atrophy, leukodystrophy 28051070
c.1925C>A p.(Thr642Asn) Two unrelated patients Hypomyelinating leukodystrophy + cerebellar atrophy; patient 1 died 16.5 y 36917474
c.2357C>T p.(Thr786Ile) Fifth family Atypical c-HSP-like, initially without apparent hypomyelination 42271096

Variant classification. All are missense variants classified as pathogenic/likely pathogenic in the recessive context. ClinVar holds 1,228 POLR1A records, of which 63 are pathogenic and 12 likely pathogenic (retrieved via NCBI E-utilities in this study); the majority of pathogenic entries reflect the dominant acrofacial dysostosis phenotype rather than the recessive HLD27 phenotype.

Variant localization — catalytic core. UniProt O95602 defines functional regions of RPA194: an RRN3-binding region (aa 468–542), a funnel (805–883), a bridging helix (960–1001), and a trigger loop (1207–1248). The three HLD27 substitutions map to catalytic-core regions: - p.Thr642Asn — downstream of the RRN3-binding region, - p.Thr786Ile — adjacent to the funnel, - p.Ser934Leu — between the funnel and the bridging helix.

Their location within the enzymatic core is consistent with a partial (hypomorphic) reduction of Pol I catalytic function rather than complete loss of function, which would be embryonic-lethal.

Population constraint supports a hypomorphic-missense mechanism. gnomAD constraint metrics for POLR1A (GRCh38, ENSG00000068654):

Metric Value Interpretation
Missense Z 5.08 Strong intolerance to missense variation (Z > 3.09 is significant)
Observed/expected missense 0.75 Fewer missense variants than expected
LOEUF (oe_lof_upper) 0.49 Intolerant to loss of function
oe_lof 0.41 (obs 84 / exp 205) ~60% fewer LoF than expected
pLI 0.22 Moderate LoF-intolerance signal

The high missense Z-score indicates that the population strongly purges missense variation in POLR1A, consistent with the interpretation that HLD27 arises from specific hypomorphic missense alleles that partially preserve viability while impairing rRNA transcription.

Allele frequency. The three causal alleles are private/ultra-rare (absent or singleton in population databases), as expected for a recessive disorder confined to a handful of consanguineous families.

Somatic vs germline. Germline, biallelic, inherited from heterozygous (unaffected) carrier parents.

Functional consequence. Partial loss of function (hypomorphic) of Pol I catalytic activity, producing reduced/aberrant rRNA transcription. This contrasts with the dominant Cincinnati-type acrofacial dysostosis alleles, which appear to act through variant-specific effects on rRNA synthesis/nucleolar morphology (see Section 6 and Evidence Base).

Epigenetic / chromosomal information. No specific DNA-methylation signature or chromosomal abnormality is associated with HLD27; the disorder is caused by point (missense) variants, not structural rearrangements.

5. Environmental Information

Environmental factors: None known to cause or trigger HLD27. Lifestyle factors: Not applicable — this is a monogenic, congenital-onset genetic disorder. Infectious agents: None; HLD27 is not infectious.

The only relevant "environmental" consideration is consanguinity/population structure, which increases the likelihood of recessive homozygosity but is a genetic-epidemiological factor rather than an environmental exposure.

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

  1. Biallelic hypomorphic missense variants in POLR1A (e.g., p.Ser934Leu, p.Thr642Asn, p.Thr786Ile) alter catalytic-core residues of RPA194 → leads to partial loss of RNA polymerase I catalytic function.
  2. Reduced Pol I activity → results in decreased transcription of rDNA into 47S pre-rRNA and aberrant rRNA processing and degradation (demonstrated in patient fibroblasts).
  3. Impaired rRNA supply → leads to disturbed nucleolar homeostasis/structure — rRNA transcription normally maintains nucleolar liquid–liquid phase separation; its loss condenses/fragments the nucleolus (model-organism/inferred).
  4. Nucleolar stress → results in release of free ribosomal proteins that bind and inhibit MDM2, thereby stabilizing p53 (TP53) (nucleolar-stress/ribosomal-stress checkpoint).
  5. Branch A — p53 activation → leads to cell-cycle arrest and apoptosis of highly translation-dependent progenitor cells (Tp53-dependent neuroepithelial apoptosis demonstrated in zebrafish polr1a⁻/⁻).
  6. Branch B — Reduced ribosome biogenesis → results in fewer monosomes/polysomes and defective protein translation, plus ER-stress and impaired protein homeostasis (shown in patient cells).
  7. Selective vulnerability of CNS cells with high translational demand (neural progenitors, oligodendrocytes) → leads to deficient myelination (hypomyelination) and progressive neuronal/glial loss.
  8. Cumulative white-matter and neuronal loss → results in the clinical phenotype: cerebellar and cerebral atrophy, ataxia, psychomotor regression, and variable spasticity.

Steps 1–2 and 6 are directly demonstrated in patient-derived material; steps 3–5 are largely inferred from Pol I model systems (mouse, zebrafish, cell lines) and the general ribosomopathy literature.

Detail by category

Molecular pathways. The central pathway is rDNA transcription / ribosome biogenesis (Pol I → 47S pre-rRNA → 28S/18S/5.8S rRNA). Downstream, the p53–MDM2 nucleolar-stress checkpoint is engaged. Patient fibroblasts showed "aberrant rRNA processing and degradation, and abnormal nucleolar homeostasis" (PMID: 36917474). Silencing POLR1A experimentally "stabilised p53" via unused ribosomal proteins binding MDM2 (PMID: 21399665).

Cellular processes. Impaired ribosome biogenesis, reduced global translation, p53-dependent apoptosis, and ER-stress/unfolded-protein responses. In zebrafish, "polr1a⁻/⁻ mutants exhibit deficient 47S rRNA transcription, reduced monosomes and polysomes and, consequently, defects in protein translation. This results in Tp53-dependent neuroepithelial apoptosis" (PMID: 29750247).

Protein dysfunction. Missense substitutions in catalytic-core regions (funnel, bridging helix, RRN3-binding vicinity) reduce Pol I enzymatic throughput — a partial loss of function. Complete loss is incompatible with life (Pol I knockouts are preimplantation-lethal).

Metabolic changes. The principal "metabolic" defect is in ribosome/protein synthesis capacity; there is no classic small-molecule metabolite deficiency. Abnormal protein homeostasis and ER stress are documented in patient cells.

Immune system involvement. No autoimmune or immunodeficiency component; HLD27 is a cell-intrinsic biogenesis defect, not an inflammatory leukodystrophy.

Tissue-damage mechanisms. Cell-autonomous apoptosis of translation-demanding progenitors and glia, driving hypomyelination and atrophy. Nucleolar phase-separation collapse (PMID: 37639467) provides a structural correlate.

Molecular profiling (patient-derived). Fibroblast studies revealed aberrant rRNA processing/degradation, abnormal nucleolar homeostasis, abnormal protein homeostasis, and ER-stress responses (PMID: 36917474). No transcriptome-wide, proteomic, or metabolomic HLD27 datasets are yet published.

Suggested ontology terms. - GO biological process: GO:0006360 (transcription by RNA polymerase I), GO:0042254 (ribosome biogenesis), GO:0006364 (rRNA processing), GO:0006915 (apoptotic process), GO:0034976 (response to endoplasmic reticulum stress). - GO cellular component: GO:0005730 (nucleolus), GO:0005736 (RNA polymerase I complex), GO:0005783 (endoplasmic reticulum). - CL cell types: CL:0000128 (oligodendrocyte), CL:0000031 (neuroblast), CL:0000047 (neural stem cell), CL:0000125 (glial cell).

7. Anatomical Structures Affected

Organ level. The brain / central nervous system is the primary affected organ (UBERON:0000955 brain; UBERON:0001017 CNS). Within the CNS, the cerebellum (UBERON:0002037) and cerebral white matter (UBERON:0002316) are prominently involved, with cerebral cortex/hemispheres atrophy (UBERON:0000956). The basal ganglia (UBERON:0002420), specifically the globus pallidus, showed T2 signal abnormality in at least one patient. Body system: nervous system.

Tissue and cell level. Primary target tissue is CNS white matter (myelinated tracts). Affected cell populations: - Oligodendrocytes (CL:0000128) — the myelinating cells; hypomyelination reflects their dysfunction/insufficiency. - Neural progenitor / neuroepithelial cells (CL:0000047 neural stem cell; CL:0000031 neuroblast) — undergo p53-dependent apoptosis in models. - Neurons (CL:0000540) — lost secondarily, contributing to atrophy.

Subcellular level. The disease is fundamentally a disorder of the nucleolus (GO:0005730), where Pol I resides and rRNA is transcribed. Secondary involvement of the endoplasmic reticulum (GO:0005783, ER stress) and engagement of nuclear p53 signaling.

Localization / lateralization. White-matter and atrophic changes are diffuse and bilateral/symmetric, typical of hypomyelinating leukodystrophies (bilateral T2/FLAIR hyperintensity with cerebellar atrophy).

8. Temporal Development

Onset. Congenital to early-childhood (pediatric). Onset pattern is insidious/chronic with early developmental delay followed by regression; the atypical c-HSP-like case had a later, spasticity-predominant presentation.

Progression. Progressive neurodegeneration. Disease course is chronic and deteriorating rather than episodic or relapsing-remitting. Patients lose acquired milestones; cerebellar and cerebral atrophy advance over time. On MRI, hypomyelination shows relative temporal stability of the T2 signal while atrophy progresses.

Disease duration and outcome. Chronic, lifelong, with reduced life expectancy — one reported patient died at 16.5 years (PMID: 36917474).

Remission / critical periods. No spontaneous remission. No validated therapeutic window is established in humans; however, model data suggest that the early developmental period of high neural rRNA demand is when cells are most vulnerable, implying that any future intervention targeting the nucleolar-stress/p53 axis would need to act early.

9. Inheritance and Population

Inheritance pattern. Autosomal recessive (biallelic POLR1A). Unaffected parents are obligate heterozygous carriers. Confirmed by the fifth-family review: "Homozygous variants in POLR1A cause an ultra-rare disorder known as hypomyelinating leukodystrophy type-27 (HLD27)" (PMID: 42271096).

Penetrance / expressivity. Penetrance in biallelic individuals appears complete; expressivity is variable, ranging from classic hypomyelinating leukodystrophy to an HSP-like phenotype, largely allele-dependent.

Epidemiology. Ultra-rare. Only ~5 families / ≈9 patients described worldwide as of 2026 — "with only four families reported worldwide to date" (PMID: 42271096). No prevalence/incidence estimates exist; effectively far below 1 per 1,000,000.

Founder effects / consanguinity. Cases arise in consanguineous unions; homozygosity for private alleles reflects shared parental ancestry rather than a defined population founder allele.

Carrier frequency. Not established; given ultra-rarity and gnomAD constraint, causal alleles are extremely rare in the general population.

Demographics. No sex predilection expected (autosomal recessive); both male and female patients are reported. No specific ethnic/geographic clustering beyond consanguineous families.

10. Diagnostics

Genetic testing (definitive). Diagnosis rests on identifying biallelic pathogenic POLR1A variants. Recommended approach: - Whole-exome sequencing (WES) or whole-genome sequencing (WGS) — the primary diagnostic modality, given clinical/genetic heterogeneity of leukodystrophies and the fact that HLD27 is not on many targeted panels. Trio sequencing aids phasing and confirmation of biallelic inheritance. - Leukodystrophy / hypomyelination gene panels including POLR1A where available. - Single-gene testing of POLR1A is appropriate when imaging and pedigree strongly suggest it, but broad NGS is generally more efficient. - Chromosomal microarray, karyotype, FISH, mtDNA and repeat-expansion testing are not diagnostically useful here (no structural or repeat mechanism).

The diagnostic-odyssey nature of unresolved leukodystrophies and the value of combining phenotyping with NGS are well illustrated in the broader literature (PMID: 37077564).

Imaging. Brain MRI is the key first-line test. Findings: diffuse, symmetric hypomyelination (persistent T2/FLAIR hyperintensity of white matter with relative temporal stability, no enhancement) plus cerebellar ± cerebral atrophy; basal-ganglia signal changes may occur. MR pattern-recognition distinguishes hypomyelination from demyelination and narrows the genetic differential (PMID: 42468917). MR spectroscopy can support characterization.

Laboratory / biomarkers. No specific blood, urine, or enzyme biomarker exists. In research settings, patient fibroblasts demonstrate aberrant rRNA processing/degradation and nucleolar/protein-homeostasis abnormalities — a functional confirmatory assay, not a routine clinical test (PMID: 36917474).

Clinical criteria / differential diagnosis. No formal diagnostic criteria exist for this ultra-rare entity; diagnosis is molecular. Key differentials among hypomyelinating leukodystrophies include: - POLR3-related (4H) leukodystrophy (biallelic Pol III subunit genes; hypodontia, hypogonadotropic hypogonadism) (PMID: 37197783), - CLDN11-related HLD22 (PMID: 42448642), - GJC2-related Pelizaeus–Merzbacher-like disease, - FOLR1 cerebral folate transport deficiency — importantly treatable with folinic acid (PMID: 37443037), - other inherited metabolic leukoencephalopathies (PMID: 42399025). The atypical HLD27 case underscores overlap with complicated hereditary spastic paraplegia (PMID: 42271096).

Screening. No newborn or population screening exists. In families with a known proband, cascade carrier testing and prenatal / preimplantation genetic testing are options.

11. Outcome / Prognosis

Prognosis is poor. HLD27 is a progressive neurodegenerative disorder with severe, cumulative disability. Reported outcomes include progressive loss of motor and cognitive function, and death in adolescence (one patient at 16.5 years) (PMID: 36917474).

  • Survival / life expectancy: Reduced; no cohort-level survival curves due to rarity. Early death is documented.
  • Morbidity / disability: Profound — ataxia, spasticity, developmental regression, dependence for daily activities.
  • Recovery potential: None with current care; the process is neurodegenerative and irreversible.
  • Prognostic factors: The specific POLR1A allele appears to be the main determinant of severity and phenotype (classic HLD vs c-HSP-like). Earlier, more severe presentations carry worse prognosis. No validated molecular prognostic biomarker exists.

Quality-of-life instruments have not been formally applied; impact is inferred to be severe.

12. Treatment

There is no disease-modifying or curative therapy for HLD27. Management is supportive and rehabilitative, mirroring general leukodystrophy care:

Supportive / symptomatic care (NCIT: C1519 Supportive Care). - Spasticity management — physical therapy, antispasticity agents (e.g., baclofen), orthotics. - Ataxia and motor support — physiotherapy, mobility aids. - Nutrition and feeding support, management of dysphagia. - Seizure management if epilepsy occurs. - Rehabilitation — physical, occupational, and speech therapy (NCIT: C15271 Physical Therapy; C15281 Occupational Therapy; C15300 Rehabilitation Therapy).

Advanced/targeted therapeutics — investigational only. No gene therapy, ASO, cell therapy, or targeted small molecule is approved or in trial for HLD27. No NCT-registered trials exist for this specific disease.

Preclinical therapeutic lead — p53 pathway inhibition. The strongest mechanistic lead comes from POLR1A model systems: in zebrafish, tp53 inhibition partially rescues the ribosomopathy/craniofacial phenotype (PMID: 29750247; PMID: 25913037). Because HLD27 pathology converges on nucleolar-stress-driven p53 activation, modulating the nucleolar-stress/p53–MDM2 axis is a rational — but entirely preclinical — therapeutic hypothesis. This must be balanced against the tumor-suppressor role of p53.

Pharmacogenomics. Not applicable.

Genetic counseling (see Section 13) is a central component of management.

13. Prevention

Because HLD27 is a congenital recessive disorder, prevention is reproductive/genetic, not environmental.

  • Primary prevention: Not achievable by lifestyle/risk-factor modification. The relevant lever is reproductive genetic counseling for at-risk couples.
  • Genetic counseling (NCIT: C15221 Genetic Counseling): For couples with an affected child or known carrier status, counseling conveys the 25% recurrence risk per pregnancy (autosomal recessive) and reproductive options.
  • Carrier / cascade screening: Testing relatives of probands for the familial variant; particularly relevant in consanguineous families.
  • Prenatal diagnosis and preimplantation genetic testing (PGT-M): Available once the familial biallelic variants are known, enabling avoidance of affected pregnancies.
  • Secondary/tertiary prevention: Early diagnosis enables anticipatory management of complications (spasticity, nutrition, contractures) but does not alter the underlying neurodegeneration. Importantly, excluding treatable mimics (e.g., FOLR1 cerebral folate deficiency, which responds dramatically to folinic acid — PMID: 37443037) is a key differential-diagnostic step so treatable conditions are not missed.
  • Immunization / public-health / environmental interventions: Not applicable.

14. Other Species / Natural Disease

  • Taxonomy / orthologs. POLR1A is deeply conserved across eukaryotes. Orthologs include mouse Polr1a (NCBI Gene 20019; Mus musculus, NCBI:txid10090) and zebrafish polr1a (Danio rerio, NCBI:txid7955). Human gene: NCBI Gene 25885 (Homo sapiens, NCBI:txid9606).
  • Natural disease in animals. No naturally occurring POLR1A-associated leukodystrophy has been reported in companion animals or wildlife (OMIA has no HLD27 entry). Notably, a different hypomyelinating leukodystrophy — GJC2-related Pelizaeus–Merzbacher-like disease — does occur naturally, e.g., a GJC2 frameshift deletion in Toy Poodles (PMID: 42543680); this is a comparative-biology reference point for HLD, not a POLR1A model.
  • Comparative biology. The ribosome-biogenesis role of Pol I is conserved from yeast to mammals, making cross-species mechanistic inference robust. Loss-of-function studies in zebrafish and mouse recapitulate ribosomopathy phenotypes.
  • Zoonotic potential: None (genetic, non-transmissible).

15. Model Organisms

Zebrafish (Danio rerio). The most informative HLD27-relevant model. polr1a⁻/⁻ mutants show "deficient 47S rRNA transcription, reduced monosomes and polysomes and, consequently, defects in protein translation… Tp53-dependent neuroepithelial apoptosis" (PMID: 29750247). Originally characterized in the context of acrofacial dysostosis, these fish established the rRNA→translation→p53-apoptosis causal chain and the partial rescue by tp53 inhibition (PMID: 25913037). ZFIN resource.

Mouse (Mus musculus). Polr1a null embryos are preimplantation-lethal (PMID: 37639467), so viable disease modeling requires hypomorphic knock-in alleles or conditional/tissue-specific deletion. CRISPR-Cas9 knock-in of human variants and lineage-specific conditional mutagenesis (neural crest, heart, forebrain) demonstrated cell-autonomous apoptosis and variant-specific effects (PMID: 37075751). High Pol I expression in neuroepithelium/neural crest explains tissue-specific vulnerability (PMID: 35881792). MGI/IMPC resources.

Cellular / in vitro. Patient-derived fibroblasts are a direct HLD27 model, showing aberrant rRNA processing/degradation and nucleolar/protein-homeostasis defects (PMID: 36917474). siRNA knockdown of POLR1A in human cell lines reproduces reduced rRNA synthesis and p53 stabilization (PMID: 21399665). hiPSCs and pharmacological Pol I inhibition recapitulate nucleolar condensation/fragmentation (PMID: 37639467).

Recapitulation and limitations. Models faithfully reproduce the core molecular cascade (Pol I loss → rRNA deficit → nucleolar stress → p53 → apoptosis) but no model specifically reproduces the CNS hypomyelinating leukodystrophy phenotype of HLD27; existing Polr1a models were built around craniofacial/acrofacial-dysostosis biology. A dedicated CNS-directed hypomorphic Polr1a mouse (oligodendrocyte/neural-lineage) is a clear gap.

Mechanistic Model / Interpretation

  Biallelic hypomorphic missense in POLR1A (RPA194 catalytic core)
p.Ser934Leu / p.Thr642Asn / p.Thr786Ile
          │  (partial loss of Pol I catalytic function)
          ▼
  ↓ 47S pre-rRNA transcription  +  aberrant rRNA processing/degradation
          │        (demonstrated: patient fibroblasts)
          ▼
Disturbed nucleolar homeostasis / phase-separation
      (nucleolus condenses / fragments)
          │
     ┌────────────┴─────────────┐
     ▼                          ▼
  Free ribosomal proteins        ↓ ribosome biogenesis
  bind & inhibit MDM2            → ↓ monosomes/polysomes
     │                   → defective translation
     ▼                   → ER stress / protein-homeostasis defect
     p53 (TP53) stabilized                │
     │                            │
     └────────────┬───────────────┘
          ▼
     p53-dependent APOPTOSIS of translation-demanding
     neural progenitors & oligodendrocytes
          ▼
     Hypomyelination + progressive cerebellar/cerebral atrophy
          ▼
   Ataxia · psychomotor regression · spasticity (HLD27 phenotype)

Upstream vs downstream. The POLR1A variant and the rRNA-transcription deficit are upstream/initiating; nucleolar stress and p53 activation are midstream amplifiers; apoptosis, hypomyelination, and atrophy are downstream effectors producing the clinical picture.

Dose/allele-dependent pleiotropy. A striking feature is that the same gene produces two distinct disorders: biallelic hypomorphic missense → recessive HLD27 (CNS hypomyelination), whereas heterozygous variants → dominant acrofacial dysostosis, Cincinnati type (craniofacial/limb), with variant-specific effects on rRNA synthesis and nucleolar morphology (PMID: 25913037, PMID: 37075751). The tissue specificity is explained by differential dependence on high rRNA output — neural crest for the dominant disorder, and CNS neural/glial lineages for HLD27.

Evidence Base

PMID Title (abbrev.) Role in this report Evidence type
28051070 Severe neurodegenerative disease in brothers with homozygous mutation in POLR1A Founding HLD27 report; p.Ser934Leu; core phenotype Human clinical
36917474 A homozygous POLR1A variant causes leukodystrophy and affects protein homeostasis Confirms hypomyelinating leukodystrophy phenotype; p.Thr642Asn; patient-cell rRNA/nucleolar/protein-homeostasis defects Human clinical + in vitro
42271096 A novel homozygous POLR1A variant: c-HSP or HLD27? Fifth family; p.Thr786Ile; confirms recessive inheritance, ultra-rarity, phenotypic variability Human clinical / systematic review
29750247 tp53-dependent and independent signaling in Acrofacial Dysostosis-Cincinnati rRNA→translation→Tp53-apoptosis cascade; p53-inhibition rescue Model organism (zebrafish)
25913037 Acrofacial Dysostosis, Cincinnati Type… POLR1A dysfunction Establishes Pol I loss → ribosome biogenesis defect → p53-dependent death Human + zebrafish
21399665 Balance of rRNA and ribosomal protein synthesis regulates p53 POLR1A silencing stabilizes p53 (nucleolar-stress mechanism) In vitro
37639467 rRNA transcription integral to nucleolar phase separation Nucleolar structure/phase-separation link; Polr1a null preimplantation lethality Mouse / hiPSC
37075751 POLR1A variants underlie phenotypic heterogeneity… Allelic series; variant-specific effects; dominant-disorder contrast Human + mouse
35881792 Dynamic regulation of rRNA transcription in development Tissue-specific vulnerability from high Pol I demand Mouse
42468917 MRI in leukodystrophies Hypomyelination vs demyelination MRI framework (diagnostics) Review
37077564 Solving inherited white matter disorders with NGS Diagnostic approach to unresolved leukodystrophies Human clinical
37443037 FOLR1 hypomyelination; folinic-acid recovery Treatable differential to exclude Human clinical
37197783 POLR3-related (4H) leukodystrophy craniofacial features Key hypomyelinating differential Human clinical

Consistency and independence. The three primary HLD27 reports come from independent groups and different alleles yet converge on the same gene, inheritance mode, imaging pattern, and mechanistic theme, strengthening causality. The mechanistic chain is corroborated across zebrafish, mouse, hiPSC, and human patient cells.

Limitations and Knowledge Gaps

  1. Extremely small sample. Only ~5 families / ≈9 patients and three alleles worldwide. Frequencies, penetrance, expressivity, sex ratio, and natural history are qualitative, not quantitative.
  2. No CNS-specific animal model. Existing Polr1a models were developed for craniofacial/acrofacial-dysostosis biology and do not recapitulate the hypomyelinating leukodystrophy phenotype; the p53-rescue evidence is from craniofacial, not CNS, endpoints.
  3. Mechanistic inference. Steps 3–5 of the causal chain (nucleolar phase-separation collapse, MDM2 sequestration, p53-driven neural apoptosis) are inferred from model systems and general ribosomopathy biology rather than demonstrated in HLD27 CNS tissue.
  4. No omics depth. No transcriptomic, proteomic, metabolomic, single-cell, or epigenomic HLD27 datasets exist; molecular profiling is limited to fibroblast rRNA/nucleolar assays.
  5. Genotype–phenotype uncertainty. Whether the c-HSP-like presentation (p.Thr786Ile) is a genuinely distinct milder end of the spectrum or an early stage before hypomyelination emerges is unresolved.
  6. No therapeutics. The p53-axis lead is preclinical, with an inherent tumor-suppressor safety tension; no trials exist.

Proposed Follow-up Experiments / Actions

  1. Build a CNS-directed hypomorphic Polr1a mouse (e.g., knock-in of p.Ser934Leu/p.Thr642Asn equivalents, or oligodendrocyte-/neural-lineage conditional hypomorph) to test whether Pol I insufficiency in CNS lineages reproduces hypomyelination and to formally test p53-pathway inhibition on myelination endpoints.
  2. iPSC-derived oligodendrocyte and cerebral-organoid models from patient cells to directly measure rRNA transcription, nucleolar integrity, translation, ER stress, p53 activation, and myelination capacity — and to screen candidate nucleolar-stress modulators.
  3. International patient registry / GeneMatcher outreach to aggregate additional families, refine genotype–phenotype correlations, natural history, and MRI evolution, and to define whether c-HSP-like cases progress to hypomyelination.
  4. Deep molecular profiling (single-cell transcriptomics, proteomics, translatomics/ribosome profiling) of patient-derived neural cells to convert the inferred causal chain into demonstrated steps.
  5. Targeted p53/MDM2-axis pharmacology in validated CNS models, carefully weighing oncogenic risk, to establish whether transient p53 dampening can preserve myelinating cells during the vulnerable developmental window.
  6. Standardized diagnostic guidance placing POLR1A on hypomyelinating-leukodystrophy panels and emphasizing MRI pattern-recognition plus exclusion of treatable mimics (FOLR1, others).

Evidence source key: Human clinical (patient reports/series), Model organism (zebrafish/mouse), In vitro (cell lines/fibroblasts/iPSC), Computational (gnomAD/ClinVar/UniProt annotation). This report synthesizes 6 confirmed findings and 23 reviewed papers from a 5-iteration investigation; the human HLD27 case literature appears saturated at three primary clinical reports.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 16
Resolved 16
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 16
On topic 12
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 30
Resolved 29
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 1
Terms whose name was checked 22
Terms named correctly 13
Terms named as a different term 6
Terms whose name is worth a second look 3

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0958018 (3 mentions) - the report calls it "MONDO"; MONDO calls it leukodystrophy, hypomyelinating, 27
  • HP:0001272 (1 mention) - the report calls it "Clinical sign / imaging"; HP calls it Cerebellar atrophy
  • HP:0002059 (1 mention) - the report calls it "Clinical sign / imaging"; HP calls it Cerebral atrophy
  • HP:0001251 (1 mention) - the report calls it "Symptom / sign"; HP calls it Ataxia
  • HP:0001257 (1 mention) - the report calls it "Sign"; HP calls it Spasticity
  • HP:0002451 (1 mention) - the report calls it "Basal ganglia abnormality"; HP calls it Limb dystonia

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • CL:0000031 (2 mentions) - the report calls it "neuroblast"; CL calls it neuroblast (sensu Vertebrata), and lists "neuroblast" among its other names
  • UBERON:0002316 (1 mention) - the report calls it "cerebral white matter"; UBERON calls it white matter, and lists "neuronal white matter" among its other names
  • UBERON:0002420 (1 mention) - the report calls it "basal ganglia"; UBERON calls it basal ganglion, and lists "basal ganglia" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

  • HGNC:17264 - called "POLR1A", "HGNC"
  • CL:0000128 - called "oligodendrocyte", "Oligodendrocytes"